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ABSTRACT 
Breast cancer is a main health problem throughout the world and it is the major cause 
of death from cancer among female worldwide. One in ten of all new cancers 
diagnosed annually in both developed and developing countries is a cancer of the 
women breast. Based on the national statistics on breast cancer in Australian women, 
37 females on average were diagnosed with breast cancer daily in 2008. Radiation 
therapy plays a major part in the management of breast cancer. It results in both 
enhanced survival rates and increased local control of the cancer.  
There are three main parts within this thesis. The first part focusses on the dosimetric 
characterizations study, which was performed for the of the newly developed n-type 
Skin diode dosimeter with 7 µm thick epitaxial layer for in vivo skin dosimetry for 
external beam breast treatments. The Silicon Diode showed a feasible response to 
different field sizes, radiation incident angles, PDD, output, entrance and exit dose 
measurements. The percentage entrance doses, as measured by the Skin diode, were 
slightly higher than doses for water equivalent depth (WED) 0.07 mm, which will be 
corrected through a re-engineering of the top encapsulating layer through subsequent 
updates of the design. The Skin diode may provide a good possibility for real-time in 




The second part of this thesis provides the investigation, which was done to study the 
feasibility of using the brass mesh bolus as an alternative to tissue- equivalent (TE) 
bolus for post mastectomy chest wall cancer. In this part, the dosimetric 
characterizations of the 2-mm fine brass mesh bolus was performed. In particular, the 
effect of brass bolus on dose build-up at the entrance surface, the beam exit, surface 
dose and beam profiles and percentage depth doses were evaluated. The cases of the 
bolus, which were used in this area, are Face-up brass bolus, Face-down brass bolus, 
double brass bolus and TE-Superflab bolus. These measurements were done in RW3 
slab phantom and curved phantom as a precursor curved contour. It was found that 
the brass mesh bolus does not significantly change dose at depth (less than 0.5%), 
and the surface dose is increased compared to TE bolus. Considering this, brass mesh 
may be used as a substitute for TE bolus to increase superficial dose for chest wall 
tangent plans. However, the effect of the mesh on surface and superficial dose when 
used in conjunction with tangential irradiation geometries is complicated and 
requires careful consideration before clinical use. 
The final part in this thesis focusses on the examination that done to investigate the 
feasibility of determining the real-time in vivo breast skin dose by monitoring doses 
during treatment and also to measure the effects of setup errors and changes in 
patient geometry on the epidermal skin dose using the MOSkinTM dosimeter for a 
range of techniques, including 3D-CRT, IMRT and VMAT. Thus, allowing the 
stability of epidermal skin dose to be compared between planning techniques of 
different complexity. 
KEYWORDS: Breast radiation therapy, in vivo breast skin dosimetry QA, Skin 
diode dosimeter, Real-time MOSkinTM dosimeter, brass mesh bolus, on-line 
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1 Chapter 1 Introduction 
1.1   Thesis introduction  
Breast cancer is a major health problem throughout the worldwide and it is the main 
cause of death from cancer among female internationally. Based on the national 
statistics on breast cancer in Australian women [1], 37 females on average were 
diagnosed with breast cancer daily in 2008. Between the period 1982 and 2008, the 
number recorded of new diagnosed breast cases was more than doubled. The age 
standardised mortality rate for breast cancer dropped to 29 %, between the period of 
1994 and 2007.  Furthermore, the 5-year breast cancer relative survival rate enhanced 
to 89 % between 2006 - 2010 comparing to 72 % between 1982 and 1987.  
Radiation therapy plays a major part in the management of breast cancer. Several 
works have been shown that the postoperative radiation therapy provides control of 
microscopic residuals of both invasive and intraductal breast cancers and an 
acceptable cosmetic outcome [2].  
Monitoring of the skin dose aids to prevent and minimise the side effects associated 
with predestined irradiation of healthy tissues such as the skin. Around 20% of 
women undergoing 3D conformal radiation therapy for breast cancer treatments 
develop acute skin toxicity which affects dramatically the quality of life of the 
patient [3].  
Currently, several radiation dosimeters have been used for in vivo skin dosimetry. 
The main difficulty in accurate skin dosimetry with the current in vivo dosimeters is 
to have small water equivalent depth (WED), as well as to have an extremely thin 
dosimetric volume to measure the dose in a radiation field with a high dose gradient 




Silicon diode dosimeters could represent a good candidate to develop a new 
technology to measure in real-time in vivo skin dose. The technology development of 
silicon diodes makes them the standard reference dosimeter for a variety of 
application in radiation therapy from quality assurance of stereotactic techniques to 
in vivo dosimetry due to their small size allowing for high spatial resolution and high 
sensitivity. 
Postmastectomy radiation therapy (PMRT) has been proven to increase the 
locoregional and the overall survival of patients with high risk breast cancer [7-9]. 
The chest wall is the most frequent site of recurrence and delivering adequate 
radiation doses to the chest wall is crucial to reducing the risk of treatment failure 
[10]. The chest wall is a challenge to treat with radiation therapy due to its irregular 
surface contours, large curvature and near-surface target tissue volume [11]. Tissue 
equivalent material bolus are commonly used during postmastectomy radiation 
therapy to provide an adequate dose build-up in the skin and superficial chest wall 
[11, 12]. Commercially available tissue-substitute materials are Superflab and 
Vaseline bolus. Previous studies have shown few limitations of using these types of 
bolus [13-15]. More details about the tissue-substitute bolus limitations are in section 
6.1. Recently, an alternative to tissue-equivalent bolus that has been used by some 
institutions is brass mesh bolus. In 2008, the Radiation Oncology Department at the 
University of California, Davis (UCD) started using a fine brass mesh bolus (Whiting 
& Davis, Attleboro Falls, MA) when delivering PMRT as an alternative to tissue 
equivalent (TE) bolus [16]. 
Nowadays, more complicated and highly conformal radiation therapy techniques, 
such as Intensity modulated radiation therapy (IMRT), have been used to treat breast 




improving the dose homogeneity and conformity over the conventional techniques 
[17, 18]. Volumetric modulated arc therapy (VMAT), which is an advanced 
extension to IMRT, is quickly being used as the best candidate RT technique to treat 
the breast cases due to its capability to deliver highly conformed dose distributions in 
a short time [19-21]. In VMAT technique, field shape, gantry speed and dose rate are 
continuously changeable during gantry rotation. 
On-line in vivo dosimetry is the most reliable and effective method, which could be 
used to check the actual dose delivery. The main benefit of the on-line in vivo 
dosimetry is that it permits for on-line dose reading, which provides real-time 
measurements during treatment. Consequently, using on-line in vivo dosimetry could 
help technicians to avoid any discrepancies between the planned and the delivered 
doses. Therefore, it enhances the treatment accuracy systematically and improves 
radiation therapy quality control [22, 23]. To the best of our knowledge, most of the 
current available in vivo dosimeters do not allow on-line delivered dose reading 
during the treatment.  
1.2   Thesis aims 
This project aims to:   
1. Investigate the feasibility of using the newly developed n- type Skin diode 
dosimeter with 7 µm thick epitaxial layer for in vivo skin dosimetry for external 
beam breast treatments. 
2. Investigate the feasibility of using the brass mesh bolus as an alternative to tissue- 
equivalent (TE) bolus for post mastectomy chest wall cancer. 
3. Investigate the feasibility of determining real-time in vivo breast skin dose during 




4. Measure the effects of setup errors and changes in patient geometry on the 
epidermal skin dose using the MOSkinTM dosimeter for a range of techniques, 
including 3D-CRT, IMRT and VMAT.  
1.3   Thesis structure 
This thesis consists of nine chapters, which will attempt to accomplish the above-
mentioned project aims and specific objectives.  
Following this introduction, Chapter 2 starts by providing a background about the 
skin dosimetry, the breast cancer and breast radiation therapy techniques. Moreover, 
this chapter gives some details about the current in vivo dosimeters.  
Chapter 3 gives a description of the instruments used in this project. It starts by 
providing a description about the newly developed Skin diode dosimeter, and then 
gives a brief information about its electronic readout system (TERA) and data 
acquisition system.  This chapter also covers some details about the other dosimeters 
used in this thesis such as MOSkinTM, and its readout system, film dosimetry, 
advanced Markus chamber and Attix ionization chamber. finally, it provides an 
abbreviated detail about the brass mesh bolus. 
Chapter 4 covers the study of the newly developed n- type Skin diode dosimeter 
characterisation on the surface of a water-equivalent RW3 slab phantom simulating 
the condition for in vivo skin dosimetry for megavoltage photon beams. The 
dosimeter calibration, linearity, Percentage Depth Dose (PDD), dose rate dependence 
and Output Factor (OF) measurement were performed. Verification and comparisons 




dosimeters, including the MOSkinTM, Gafchromic EBT 3 film and the Attix 
ionisation chamber. 
Chapter 5 covers the field size and angular dependence of the newly developed n- 
type Skin diode dosimeter, as well as the surface dose and exit dose measurement 
were done in this chapter. 
Chapter 6 assesses the feasibility of using the brass mesh bolus as to tissue- 
equivalent (TE) bolus for post mastectomy chest wall cancer. This chapter provides 
the effect of brass bolus on dose build-up at the entrance surface, the beam exit, 
surface dose and beam profiles and percentage depth doses by using MOSkinTM, EBT 
3 Film and advanced Markus chamber. Additionally, the study of the effect of of the 
brass mesh construction on the skin dose on curve phantom is outlined in this 
chapter.  
Chapter 7 outlines specifically, the effect of the brass mesh construction on the skin 
dose. Dose beam profile measurements at different depths measured with EBT 3 
Film and the Face-up brass versus Face-down brass bolus measurements with 
MOSkinTM were performed in this chapter. 
Chapter 8 assesses the feasibility of determining real-time in vivo breast skin dose by 
monitoring doses during treatment with a MOSkinTM dosimeter. This chapter aimed 
to measure the effects of setup errors and patient geometry shifts on the breast skin 
dose and pick up inconsistencies at any stage of treatment delivery. The measured 
doses were compared with the planned doses across the whole course for each 
treatment arc and field delivered. This objective achieved by creating three VMAT 
plans for Flattening Filter Free (FFF) MV photon beam using Acuros XB algorithm 




Chapter 9 concludes this thesis by summarizing of the outcomes of each chapter and 

















2 Chapter 2 Literature Review 
2.1   Skin dosimetry  
Skin comprises of two main layers, which are epidermis and dermis, as shown in 
Figure 2-1. The superior layer is the epidermis, which is approximately 1.5 mm thick 
in the foot base and 0.04 mm in the eyelid. The dermis is positioned under the 
epidermis and has two layers: the subcutaneous fat and the connective tissue, which 
are located under the dermis [24]. 
 
Figure 2-1 The human skin layers diagram, illustrating the epidermis (including the 
squamous cell and basal cell layers), dermis, subcutaneous tissue, and other skin 
parts [25]. 
 
The skin is a sensitive organ to the radiation and the shallow layer of basal cells of 




toxicity. The depth of the basal layer of the epidermis is range of approximately 40 – 
60 μm deep [26]. However, the epidermis thickness varies from one individual to 
another and from one location to another in the same person. In the person body,  
thickness of the epidermis varies from approximately 1.5 mm in palm of hands and 
feet  to 0.05 mm in eyelids [26]. The International Commission on Radiological 
Protection (ICRP) recommends 0.07 mm as the estimated depth for the basal layer 
and 1.0 mm for the dermal layer [27, 28]. 
Several experimental studies have been performed to investigate the pathophysiology 
of the effects of ionizing radiation on the skin. These works have presented the 
relation between the basal-cell carcinoma (BCC) induction and the radiation therapy  
[26, 29].  
The exposure of the skin to the ionizing radiation can cause several response phases 
that depend on the exposure conditions. The early phase is the transient early 
erythema (redness, rash-like appearance), which can be seen within a few hours (24 – 
48 h) of irradiation. The main erythematous reaction -the varying severity of loss of 
epidermal basal cells; either a dry or a moist desquamatory response- can be seen 
after 3 - 6 weeks. The late phase of erythema is dermal ischemia and possibly 
necrosis that starts after 8 - 16 weeks, and the late skin damage, which includes the 
dermal atrophy ( > 26 weeks), and finally the telangiectasia and necrosis ( > 52 
weeks) [26]. 
The dose delivered to the skin is influenced by many factors. Some of these factors 
are related to the treatment techniques and the treatment protocol, and some other 




2.2   Breast cancer 
Breast cancer is a main health problem throughout the world and it is the major cause 
of death from cancer among females worldwide. One in ten of all new cancers 
diagnosed annually in both developed and developing countries is a breast cancer 
[30]. Ferlay et al. [31] reported that more than 1.1 million cases are diagnosed and 
more than 410,000 patients die of it internationally. Currently, it is the most 
common cancer globally for females and it is the second cancer after the lung.  
This increased incident rate has necessitated the development of advanced treatments 
to treat the disease. 
Radiation therapy plays a major part in the management of breast cancer. Clarke et 
al. (2005) reported that the postoperative radiation therapy has been demonstrated to 
reduce the risk of any recurrence of breast cancer by a half and breast cancer-related 
mortality by a sixth in patients with early breast cancer [32, 33].  
2.3   Breast radiation therapy techniques 
Breast cancer radiation therapy  has improved dramatically over the past century. It 
is well established as a treatment for early breast cancer patients. Many works 
reported that radiation therapy results in both enhanced survival rates and increased 
local control of the cancer [34]. A variety of different radiation therapy modalities 






Figure 2-2 Beam arrangements for the different modalities used to treat breast 
cancer. (a) 3D-CRT with two wedged tangential fields. (b) IMRT with two Fields 
with different intensities. (c) VMAT with two partial arcs. 
2.3.1 Three-dimensional conformal RT (3D-CRT) 
3D-CRT demands a computed tomography (CT) scan to design a radiation therapy 
treatment that is individualised to each patient. It is the combination of two 
dimensionally shaped coplanar and opposed beams that create a three-dimensional 
high dose region that approximates the shape of the cancer. Conformal radiation 
therapy uses the targeting information to deliver a conformal dose of radiation to the 
tumour while sparing the normal tissue surrounding the tumour as much as possible. 
This technique uses either physical wedges or dynamic wedges to improve the dose 




2.3.2 Intensity-Modulated Radiation Therapy (IMRT) 
IMRT is a treatment technique that permits modulation of the beam intensity within 
the treatment fields with multileaf collimators (MLCs) to obtain highly conformal 
dose delivery. Each IMRT beam does more than simply conform to the shape of the 
cancer in two dimensions. It actually varies the intensity of the RT absorbed dose 
according to the extensions of the cancer in three dimensions. A single IMRT beam 
is formed of many small beamlets, each with a different intensity. Treatment beams 
for very complicated target volume shapes can be created, with rapid fall-off of dose 
immediately outside the target volume. IMRT improves the dosimetry of 3D-CRT 
and is often compared with 3D-CRT in clinical studies. 
The purpose of IMRT is to enhance the dose delivered to the target in order to 
achieve higher local tumour control rates, without a corresponding increase in 
normal tissue toxicity. 
Initial data indicate that tumour control after IMRT is superior to results from 3-D 
CRT. The beam shaping and variation in dose intensity of IMRT is done specifically 
for each cancer patient and is personalised RT. 
There are two types of IMRT in breast radiation therapy. The first type is Forward 
planned IMRT, such as Field in Field- IMRT (FiF-IMRT). In Forward planned 
IMRT, the weight of the treatment fields and the field shapes are determined by the 
user. Whereas, in inverse planned IMRT, the objectives to various organs can be set 
and then the algorithm with density scaling produces freely modulated fluence 
weight profiles [35].  
IMRT has a major role in improving the quality of life for females who receive RT 
and limiting acute and chronic toxicity [36, 37]. The advantages of IMRT over 3D-




volumes and improved sparing of organs at risk (OARs) and normal tissues, and thus 
result in reduced acute and late toxicities. Additionally, IMRT has the ability to 
produce inhomogeneous dose distributions, which allows the simultaneous delivery 
of different doses per fraction to separate areas within the target volume. In other 
hand, there are still some disadvantages with this technique, such as the planning and 
quality assurance (QA) processes required for IMRT are more complex and time-
consuming compared with 3D-CRT techniques, which can have significant impact 
on departmental resources [38]. 
2.3.3 Volumetric Modulated Arc Therapy (VMAT) 
Volumetric modulated arc therapy (VMAT) was first implemented in 2007 and it 
was described as a novel radiation therapy technique that is able to vary a rotational 
geometry and beam modulation achieved via continuous modulation of multileaf 
collimator, dose rate variations and gantry rotational speed dynamics [39]. 
Compared to static IMRT, VMAT may allow for better dose conformity, lower 
maximum dose to OARs and delivery time. More recently, VMAT techniques have 
allowed the whole target volume to be treated using one or two arcs, although 
complex cases may require larger number of arcs [38]. 
2.4   Effect of treatment Techniques on the skin dose  
Numerous studies have been reported that the treatment techniques contributed to the 
skin dose such as the use of immobilization masks, tangential fields, the blocking 
tray, target contouring and the optimization during IMRT inverse planning [29, 40-
48]. 
Many authors have investigated the skin dose resulted from using conventional 




Kry et al. [29] summarised the effect of the treatment factors on the surface dose. 
They reported that the surface dose increases proportionally with field size. Several 
studies have found that the surface doses decreased as the energies increases, 
whereas other studies have not, especially with larger field sizes. In addition, the 
surface dose differences are small with the nominal energy. Unlike nominal energy, 
the Co-60 produces a higher surface dose that also enhanced with field size, ranging 
between 20 % – 85 % of the dmax dose. Although the effect of the SSD is relatively 
small approximately 10 % relative changes with SSD change from 100 cm to either 
85 or 120 cm, it can exceed 20 % for large fields ( ≥ 20 × 20 cm2) when other 
modifying devices, such as blocks, are involved [29].  Kry et al. reported that the 
presence of the physical wedges reduced the surface dose, whereas, the dynamic 
wedges have a negligible influence on the surface dose relative to open fields. 
However, there were some investigators who demonstrated the opposite, for example 
Siyong et al. They summarised that comparing to the skin dose from standard 
physical wedges, the influence of dynamic wedges on skin dose was more. Other 
work has reported the difference between open field doses and EDW doses were 
within 0.3 %. The surface doses for the physical wedge fields were less than for the 
open fields, and these doses decreased with increasing wedge angle [49]. Moreover, 
it was reported that the skin dose measured with the parallel-plate chamber increased 
as field size increased from 6 % with 5 × 5 cm2 to 38 % with 40 × 40 cm2 field size 
for 8 MV and 5 % to 44 % for 18 MV photon beam. The presence of an acrylic block 
tray increased the surface dose for all field sizes. It enhanced the surface dose from 7 
% to 59 % for 5 × 5 cm2 to 40 × 40 cm2 respectively, for 8 MV and 5 % to 62 % for 
18 MV beam [50]. Butson et al. and other authors proved that the skin dose increases 




especially for larger field sizes. Some studies have reported that the relative increase 
was 10 % – 20 % and about 50 % for 25 × 25 cm2 and 40 × 40 cm2 field size, 
respectively, however this increase was not significant for small filed sizes such as 5 
× 5 cm2 [51]. 
Lee et al. studied the skin toxicity as a consequence of an increase in skin dose from 
multiple fields extended intensity modulated radiation therapy (Ex-IMRT) for head 
and neck (H&N) cancer. He concluded that this reaction resulted from causes such as 
the immobilisation masks used during irradiation, or the inverse treatment planning 
system. They observed that the skin reaction can be reduced to 18 % if the skin was 
defined as sensitive organ during inverse planning [48]. Roland et al. evaluated the 
skin dose from three RT techniques, Helical TomoTherapy, Serial TomoTherapy, 
and IMRT, for prostate and H&N cancers, and found that Helical TomoTherapy 
deposits the highest skin dose in prostate and H&N, followed by Serial 
TomoTherapy, and IMRT being the lowest [52]. Dogan et al. found no difference 
between skin doses using open field conventional RT and IMRT for an oblique 
angle. Any increase in the surface dose was found to be a result of a shift in the 
build-up region caused by an oblique angle [47]. 
Higgins et al. reported that dynamic treatment techniques, such as TomoTherapy and 
IMRT afforded approximately 2 – 13 % higher surface doses, relative to the 
prescription dose, than simple bilateral fields, with measured dose averages of about 
82 % of the target dose for the right lateral surface for IMRT, 71% for TomoTherapy 
and 69 % for bilateral treatment. In Higgins’s study, the bilateral technique showed 
the lowest doses for the anterior to the target volume where, the minimum anterior 
surface dose was 6 % of the prescription dose from this technique as compared with 




it was reported that the depths at which doses reach 99 % or more to be the 
shallowest for IMRT (2 – 5 mm) followed by TomoTherapy (5 – 8 mm) and bilateral 
fields (10 – 15 mm) [40]. In contrast, Akino et al. evaluated the dose calculation 
accuracy for the superficial dosimetry for the breast irradiation with EBT 2 film 
measurements using a phantom for four different breast treatment techniques. They 
concluded that the IMRT calculation underestimated superficial dose at 3 mm by 
19.1% when using with routinely (2.5 × 2.5 mm2) grid size calculation. It was 
concluded that the calculated surface dose (with whatever planning system they 
used) was lower than measured value using EBT 2. In addition, the 7-field IMRT 
showed reduction of surface dose compared to tangential wedged fields as it 
calculated with the TPS [53]. Capelle et al. investigated the skin dose received for 
patients receiving adjuvant breast radiation therapy (RT) with standard three-
dimensional conformal RT (3D-CRT) and skin-sparing helical TomoTherapy (HT) 
by using optically stimulated luminescence dosimeters (OSLs) or TLDs. It was found 
that generally, the HT-calculated dose overestimated the measured dose by 14 %, 
while 3D-CRT underestimated the dose by 0.4 %. Capelle et al. concluded that the 
calculated dose determined by the 3D-CRT TPS more accurately reflects the 
measured skin dose than the HT TPS, which tended to overestimate skin dose in 
patients undergoing adjuvant breast RT [54]. Kry et al. reported that the 
immobilization devices such as thermoplastic masks increase the skin dose from 16 
% to 40 % of the dmax dose with a lightly stretched mask [29].
 Kelly et al. measured 
the skin dose in the presence of the thermoplastic immobilization casts (Orfit) for a 
clinical conformal and IMRT breast plan using the radiochromic film and MOSkinTM 
dosimeters at a range of water equivalent depths representative of the different skin 




in the skin dose up to 50 % of the skin dose without the immobilization cast as 
measured with two different dosimeters. It was reported that the surface dose 
increased with the increase of beam obliquity and cast thickness. The surface dose 
increased to an approximately 35 % and 48 % for the thinner and thicker cast 
material, respectively, compared without immobilization cast at 00 under a gap in the 
cast, while at 750, the surface dose increased to 51 % and 60 % for the thinner and 
thicker cast material, respectively [41]. Kelly et al. results agreed with Fiorino et al. 
results, who concluded that the masks are the main cause of the increase in surface 
dose. It was found that the surface dose with 2 mm Orfit thickness, increased the 
surface dose by more than 40 % and as the Orfit thickness increases to 3.5 mm, the 
surface dose increased to about more than 60 %. Moreover, the surface dose 
increased slightly with the presence of the blocking tray and increased field sizes but 
reduced slightly with the presence of the wedge. Fiorino et al. suggested to elminate 
the influence of the tray and blocks on the surface dose, by introducing thin metal 
plates between the blocking tray and patient and opening a window on the mask [42]. 
Quach et al. investigated the effect of a curved contour with two chest wall tangent 
fields and compared measurements of superficial doses using different detectors, 
including radiochromic film (effective depth of 0.17 mm), TLD (effective depth of 
0.14 mm), and MOSFET (effective depth of 0.5 mm). They concluded that skin dose 
increases with increasing surface curvature, where the maximum was found at 900. 
Moreover, they used an alternate bolus on, bolus off regimen, and found that the skin 
received 36.8 Gy at 0° and 46.4 Gy at 90° incidence for a prescribed midpoint dose 
of 50 Gy without bolus. Adding 1cm bolus caused a large increase about 350 % in 
dose at shallow incident angles (< 60°) but at steep incident angles (> 140°) the 




Several possible strategies for avoiding the increase of the skin dose have been 
discussed by many authors, which can be used for all treatment techniques. Some of 
these strategies are the use of the skin as an organ at risk, modification of the PTV to 
avoid the skin, and the use of pretend bolus applied in planning but not in treatment. 
For sparing the skin dose in IMRT, various possible strategies have been discussed, 
including the delineation of the skin as an organ at risk, the use of a hypothetical 
bolus applied in planning, but not in treatment, and the use of a PTV shrinkage 
margin from surface [42, 44, 55]. An-Cheng et al.  reported the surface dose 
decreased with increasing shrinkage margin [44]. Thomas and Hoole reported that 
the IMRT delivery does not increase skin dose, but the inverse planning can result in 
increased skin dose that is due to the requirement of PTV-based optimization to 
minimise objective functions, and hence to remove regions of low dose from the 
PTV, even where these are caused by the build-up effect. They evaluated the impact 
of including or excluding skin or in adding a ‘pretend’ bolus to artificially extend the 
surface, to avoid the hot spot formation. Laurence et al.  evaluated different IMRT 
planning strategies to reduce skin dose, including measurements of skin dose and 
doses measured at various depths by using micro-MOSFET dosimeters on the semi-
cylindrical phantom. they reported that the doses to the skin and structures near the 
body surface can vary by up to 20 % of the prescribed dose, depending on the PTV 
expansion and IMRT optimization technique used. Comparing between the skin dose 
with and without an immobilization mask, this study showed that the bolus effect of 
the mask was a significant contributor to skin dose in head-and-neck IMRT. 
Laurence et al. concluded that the dose to the skin can be reduced if the skin 




the PTV if unwanted reductions in dose to nodes near the body surface are to be 
avoided [46]. 
Based on the traditional fractionation schedule, 1.8 to 2 Gy fraction dose is delivered 
daily to a total of 45 to 50 Gy for breast treatment. This fractionation schedule 
presumes smaller fractions diminish the late normal tissue toxicity without 
compromising tumour control [3, 56]. Bentzen at el. (1990) [57] concluded in their 
study that the late side effects are more sensitive to changes in fraction sizes 
compared to acute side effects, so to maintain the normal tissue toxicities, the total 
radiation dose must be reduced if the fraction sizes are to be enhanced [58]. 
2.5   Treatment Planning Systems (TPS) algorithms 
An accurate calculation of the dose on the surface and build-up region is still a 
challenge for the available treatment planning system algorithms.  This is mainly due 
to difficulties in modeling the contribution of doses from contaminated electrons 
produced from flattening filter, collimator assembly and, to a lesser extent, secondary 
scatter photons from the accelerator head [59]. Moreover, plenty of studies have 
examined and compared different types of calculation algorithms and they have 
concluded that the deviations are above 2 % in heterogeneous tissue even for the 
advanced algorithms [60]. Several works have been performed to evaluate the 
accuracy of the calculation algorithms [53, 54, 59, 61-63]. Lu L. ranked the dose 
calculation algorithms based on their accuracy. It was concluded that the Monte-
Carlo algorithm was the most accurate algorithm followed by the Acuros XB, CCC, 
Anisotropic Analytical Algorithm (AAA), Pencil Beam Convolution (PBC) 




Oinam et al. tested the accuracy of the AAA and PBC algorithms for Eclipse 
Treatment Planning Systems (TPSs), to verify the IMRT dose calculations in the 
low- and high-dose build-up regions. They concluded that the AAA calculated the 
dose more accurately than PBC in clinically important high-dose build-up region at 
0.4 cm and 0.6 cm depths. However, both algorithms have limitation in calculated 
dose at 2 mm depth. Chung et al.  investigated the dose at the surface and in the 
build-up region for MLC-based IMRT treatment for a head and neck using 
radiochromic film in semi-cylindrical solid water slabs. They evaluated the 
superficial and build up doses for two different target volumes located in the 
phantom, the shallow located target at 0.5 cm depth and the deep located target at 6.0 
cm depth by planning with two different commercially available TPS (CORVUS and 
Philips PINNACLE3). Chung et al. concluded that both TPSs overestimated the 
surface dose for both shallow and deep located targets by the amount of 7.4 % to 
18.5 % with respect to the prescribed dose. Additionally, it was concluded that there 
were significant differences in surface doses at depth of 2 mm or less [61]. Roland et 
al. concluded that the TPSs overestimate average skin dose compared to TLD 
measurements by 30 % for TomoTherapy TPS (helical tomo-delivery), 43 % for 
Corvus TPS (serial tomo-delivery) and 15 % for pinnacle TPS (IMRT-S&S delivery) 
[52]. Higgins et al. concluded that the Eclipse and TomoTherapy planning systems 
calculated dose accurately in the build-up region and at depth and reasonably 
accurate at the surface. TomoTherapy consistently overestimated the measured 
surface doses by 10 % or more, so the Eclipse predicted the surface doses better than 
the TomoTherapy system [40]. Capelle et al. concluded that the calculated dose 




than the HT TPS, which tended to overestimate skin dose in patients undergoing 
adjuvant breast RT [54]. 
An-Cheng et al. evaluated the accuracy of the TPS calculated doses in the build-up 
region. Moreover, it was found that the accuracy of dose calculation in the superficial 
region for a TPS does not depend on different PTV shrinkage margins, but on the 
dose calculation algorithm. Differences > 10 % between calculations and 
measurements can be found at depths < 3 mm. The accuracy of dose calculation is 
more reliable at a deeper depth; the difference is < 5.5 % (average 2.5 %) at a depth 
of 7.0 mm. There was no significant dependence of calculation accuracy with 
different shrinkage margins. An-Cheng et al. suggested that the accuracy of the TPS 
calculation can be improved if the electron contaminations are taking in to account, 
since the main source of skin doses is the contamination radiation from machine 
head, and air and backscattered radiation from the patient.  An-Cheng et al. results 
agreed with Ezzell who reported that if the TPS underestimates the dose in the 
superficial region, the inverse planning algorithm will correspond low doses in the 
build-up region and then increase the intensities incorrectly. These modulations may 
cause high doses to the superficial regions if the TPS underestimates the dose in the 
build-up region [44]. Kroon et al. evaluated the Acuros XB for lung cancer patients 
(SBRT) in a heterogeneous rectangular slab phantom and found that Acuros XB 
calculations lower near-minimum PTV dose and mean PTV dose than the plans 
calculated by analytical anisotropic algorithm (AAA) and they concluded that the 
AXB is more accurate to use for the dose calculations in SBRT lung plans created 
with a VMAT technique  [65] . 
Akino et al. found that the accuracy of the TPS calculation improved as the grid size 




by 14.7 % on average of medial region, whereas, the calculation with 1 × 1 mm2 grid 
size showed a slightly smaller difference between calculation and measurement, i.e. 
10.0 % on average of medial region.  However, the calculated dose profiles with both 
2.5 × 2.5 mm2 and 1 × 1 mm2 grid size showed good agreement at greater depths (6 
and 11 mm) with the measurements. Akino et al. concluded that the accuracy of 
advance algorithm such as AAA is not sufficient for calculating superficial dosimetry 
in breast treatment and they also ended that the grid size plays an important role in 
dose calculation, hence a smaller calculation grid should be used for superficial 
dosimetry [53].  
Panettieri et al. quantified the dose differences in the build-up region, near the skin 
of a patient, and the dose distributions between the commercial TPS Eclipse 
algorithm (PBC & AAA) calculation and Monte Carlo (MC) simulations using the 
PENELOPE code. They concluded that the small grid size (of the order of 2.5 mm) is 
recommended to account correctly for the dose in the build-up region. The algorithm 
of the PBC calculation for 6 MV and 10 ×10 cm2 field size with 150 gantry angle 
using grid sizes of 2.5 – 5 and 10 mm calculated very differently in the build-up 
region for the three grid sizes with differences up to 5 mm at the 60 % dose level. In 
contrast, for AAA calculation, which allows the use of grid sizes ranging from 2 to 5 
mm, got that a change in the grid size does not affect the resulting absorbed doses. 
The differences were less than 0.7 mm at 60 % dose level. 
Unlike 6 MV, in comparison to MC data for 18 MV, both AAA and PBC tend to 
overestimate the dose in the first 5 mm of the build-up region for all cases except for 
larger angles of incidence, such as 750, for which both PBC algorithm and AAA tend 




Several studies have also investigated the clinical use of Acuros XB. The accuracy of 
Acuros XB was reported to be within 5 % up to 2 % when compared to the MC 
calculations. Han et al. verified the dosimetric performance of Acuros XB (AXB), a 
grid-based Boltzmann solver, in IMRT and VMAT by two dosimeters 
thermoluminescent dosimeter (TLD) and Gafchromic EBT 2 film measurements in 
Radiological Physics Centre (RPC) head and neck (H&N) phantom. It was reported a 
good agreement between the TLD measured doses and the calculated dose values. 
Both algorithms (AXB_Dm,m and AXB_Dw,m) were mostly within 5 % of the TLD 
measurements in both the IMRT and VMAT plans.  Generally, the IMRT and 
VMAT dose profiles from AXB agreed well with those from the films, whereas, the 
AAA calculated doses were higher than those from film and AXB. From the profile 
comparison, it can be observed that the displacements of the measured penumbra 
were all within 1.5 mm DTA in all cases, which were all in good agreement to the 
planning. 
The spatial distribution of the gamma analyses with 5 % / 3 mm criteria of the 
VMAT and IMRT plans showed that the difference between measured film doses 
and the calculated with AXB_Dm,m and AXB_Dw,m were relatively small,  and the 
areas of dose differences between measured and calculated doses were slightly larger 
when doses were calculated with AAA rather than with AXB. Han et al. stated that 
the agreement between measured and calculated film doses was worse for VMAT 
plans than for IMRT plans. For both IMRT and VMAT, more than 88 % of the pixels 
passed the 5 % / 3 mm criteria for AXB, but the AAA had only an 80 % – 85 % 
passing rate. Moreover, it was concluded that the AAA computation times were 2 to 
3 times faster than AXB for IMRT, but the AXB time was about 4 - 6 times faster 




calculated with AAA and AXB were found very similar for normal tissue structures, 
but some outstanding differences in PTVs (primary and secondary) and OAR 
structures were observed. The percent differences in mean dose between AXB and 
AAA were within 2 % in normal tissue, 5 % in PTVs, and 7.5 % in OAR structures. 
The differences between the AAA and AXB DVHs of the IMRT plan were larger 
than those between the AAA and AXB DVHs of the VMAT plan [62]. Hoffmann et 
al. tested the accuracy of grid-based linear Boltzmann transport equation (LBTE) 
technique algorithm in both heterogeneous and homogeneous media for both 6 MV 
and 15 MV photons in a range of clinical situations including variable SSD, 
asymmetric fields, as well as for IMRT and VMAT treatment plans and then 
compared the performance of the algorithm with ionization chamber, diamond 
detector and film measurements and AAA algorithm calculations. Generally, both 
algorithms underestimated the dose in the low dose region just outside the jaws, 
while in the high dose region close to the penumbra; they overestimated the dose. 
These deviations were far more evident for 6 MV photons than for 15 MV photons.  
In heterogeneous media, using Acuros XB algorithm, the percentage of points 
achieving the Gamma criterion was 98.2 % and 99.5 %. 
Using AAA, the percentage of points achieving the Gamma criterion was 94.0 % for 
6 MV and 96.1 % for 15 MV photons. Both algorithms overestimated the dose to 
part of the lung by up to 5 % using Acuros XB and up to 8 % using AAA in a 
number of the treatment plans. For 15 MV, only very small deviations were seen 
when using Acuros XB. In addition to the overestimation in lung, the AAA algorithm 
also overestimated the dose close to the vertebral body, by up to 8 % in a number of 
the treatment plans. Hoffmann et al.  concluded that the dose calculations done by the 




measurements and AAA. However, in heterogeneous media, the Acuros XB 
algorithm is superior to AAA in both lung and bony material [63]. 
2.6   In vivo skin dosimeters 
The main difficulties in accurate skin dosimetry with the current in vivo dosimeters 
are to have small water equivalent depth (WED), as well as to have an extremely thin 
dosimetric volume to measure the dose in a radiation field with a high dose gradient 
at the media interface [4-6]. The International Commission on Radiation Units & 
Measurements (ICRU) recommends that the depth of measurement for skin dose for 
practical purposes should be performed at a WED of 0.07 mm, relating to the 
average depth of the basal cell layer and often at the site for early skin reactions [66]. 
Currently, a variety of radiation dosimeters have been used routinely in the 
measurement of the build-up region, the surface dose and the in vivo skin dosimetry. 
The effective thickness or effective point of measurement of a skin dosimeter can 
have a significant effect on the skin dose measured or calculated. The most common 
in vivo dosimeters that have been used to measure the surface and skin dose by the 
investigators are: a parallel-plate ionization chamber [5, 42, 47, 49, 50, 67], film 
dosimeters [49, 68-74], Thermoluminescence dosimeters (TLDs) [75-79], optically 
stimulated luminescent dosimeters (OSLDs) [80], fibre optic coupled scintillation 
dosimeters [81], and Metal Oxide Silicon Field Effect Transistors (MOSFETs) [6, 
76, 77, 82-88] including the MOSkinTM [84, 89-95]. 
2.6.1 Parallel Plate ionization chambers  
Many previous studies have considered the extrapolation ionization chamber, which 
is a type of parallel plate chamber Figure 2-3, as the reference instrument for the 




variable volume. The limitations of these type of chambers are that they are time 
consuming, and quite complicated to obtain a measurement. Hence, it is not routinely 
used for skin dosimetry [96].  
 
Figure 2-3 NACP Plane-Parallel design of ionization chamber [97]. 
 
The Attix chamber is a type of fixed-separation parallel plate detector used to 
measure superficial skin dose due to its very shallow effective point of measurement 
of 48 μm which enables highly accurate measurements of surface dose [98]. The 
effective point of measurement is on the inner surface of the entrance window, so the 
thickness of the entrance window is a significant factor that determines the depth 
below the surface at which measurements are made. The entrance window of the 
Attix chamber is only 0.025 mm thick and made of Kapton, which has density of 
1.42 g/cm3 , which is larger than water density [95].  
Due to their accuracy for in-phantom measurements, the Attix ionization chambers 
are generally considered as the reference dosimeter for interface dose measurement. 
The limitations of the Attix ionization chambers include: they can be used only for 
skin dosimetry in a phantom, they cannot be used for patient skin dose measurements 
as they have a high polarizing voltage, large size and rigid geometry [5, 71]. 




they also have been never manufactured in array for skin 2D dose mapping [99]. 
Some other authors have used Markus-type ionization chamber which is another type 
of fixed parallel-plate ionization chamber to measure both the maximum dose and 
the skin dose. The Markus-type chamber has a small guard ring that is 0.1 mm wide. 
The entrance window mass thickness is 2.7 mg/cm2 [50]. 
2.6.2 Thermoluminescent dosimeters (TLDs) 
The thermoluminescent dosimeters (TLDs) are widely used for in vivo dosimetry. 
There are many authors who used TLDs because of their small size and tissue 
equivalence. The limitations of TLDs include they require careful, time-consuming 
handling and annealing procedures. They also demand frequent calibration and a 
long series of pre- and post-irradiation process [43, 59, 78]. TLD is not suitable for 
skin dosimetry because it has an effective WED of 0.8 mm, which is larger than the 
WED for the ICRP recommended skin depth [79]. Furthermore, the reproducibility 
of TLD measurements is not good. The TLD dosimeters can only be used to check 
discrete points [43]. In addition, TLDs are not capable of providing real-time 
dosimetry [69]. 
In most cases, TLDs are used in vivo for special treatment procedures such as total 
body irradiation (TBI), total skin electron irradiation (TSET), and unusual treatment 
configurations, or to monitor doses to critical structures [76].  
Kron at el. (1996) used different thicknesses of TLDs to measure entrance and exit 
skin dose [77]. 
2.6.3   Film dosimetry 
Presently, Gafchromic film has been used widely as skin dosimeter in radiation 




high planar spatial resolution, low spectral sensitivity, tissue equivalency, large 
dynamic range (10-2- 106 Gy), energy independence, insensitivity to visible light and 
self-development. In addition, the film is light weight so it can be bent and cut to any 
size or shape to be used clinically and it can be handled in visible light. The 
Radiochromic film can be used in the dose range from 10 to 100 Gy [43, 71, 98]. 
However, films are passive detectors and they do not support real-time 
measurements. 
When compared to film verification, the advantages of using TLD included the 
verification of doses at specific points of interest and the allowance of different beam 
orientations relative to the detectors.  
Gafchromic EBT film was initially introduced in radiation therapy in 2004. The 
structure of EBT model in shown in Figure 2-4. The International Specialty Products 
(ISP, Wayne, NJ) then released a new film generation, Gafchromic EBT 3 film in 
2011 [73]. Many works have been done to study the properties and characterizations 
of EBT films. Some of these studies reported that the doses measured with 
Gafchromic EBT film are in good agreement with the Attix parallel-plate chamber 
results and the uncertainty of dose measurement using EBT film ranges from 3.3 % 





Figure 2-4 EBT structure. 
 
Recently, the new generation of Gafchromic films, EBT 3, has become a popular tool 
to verify dose distributions in highly conformal radiation therapy such as IMRT. 
Although EBT 3 has the same composition and thickness of the sensitive layer of the 
EBT 2 films, the orientation dependence with respect to film side, present in previous 
versions, was completely eliminated in EBT 3 films. On the downside, films are time 
consuming and do not allow for the real-time measurements.  
EBT Gafchromic films have been investigated to be used for in vivo surface 
dosimetry in megavoltage photon beam fields. Nakano et al. found that the doses 
measured with Gafchromic EBT 2 film were in good agreement with the Attix 
parallel-plate chamber results.  Nakano et al.  concluded that the Gafchromic EBT 2 
film can be suitable for in vivo surface dosimetry in megavoltage photon beam fields. 
Roland et al. showed that the Gafchromic films quantified the average skin dose to 
within 10 % of the values measured by the ultra-thin TLDs for all the IMRT delivery 




Devic et al. determined a correction procedure in order to obtain an accurate skin 
dose estimate at the clinically relevant depth based on radiochromic film 
measurements, within a Solid Water phantom exposed to 6 MV photon beam. It was 
measured the correction factors for the entrance skin dose estimation (skin depth was 
assumed to be at 70 μm) for each dosimeter, and found that the Gafchromic films 
required a significantly large correction factor, for example 15 % for EBT, 15 % for 
HS, and 16 % for XR-T model, while the Attix parallel-plate ionization chamber 
underestimated the skin dose by 6 %. The correction factors for TLD was determined 
to be 0.810 (a 19 % change) for 0.15 mm thick and 0.586 (41 % correction) for 0.4 
mm thick TLD chips. Their PDD measurements were in good agreement with Monte 
Carlo simulations except at very shallow depths, below approximately 10 μm. 
Additionally, the PDD measurements by EBT strip and an ionization chamber in the 
build-down region showed that the measured build-down was in good agreement 
with previously published data. In contrast, it was stated that if any of the three 
Gafchromic film models were used for the estimation of the exit skin dose, a 
maximum correction of 0.3 % is required if the skin depth was assumed to be at 70 
μm. Over a range of field sizes from 5 × 5 cm2 to 30 × 30 cm2, their measurements 
have also shown that the skin dose correction for the effective point of measurement 
in the build-down region was of the order of 0.3 % for all three Gafchromic film 
models. In contrast, in the build-up region, a change of the field size resulted in a 
change of the entrance skin dose scaling factor for EBT film model from 0.80 for a 5 
× 5 cm2 to 0.93 for a 30 × 30 cm2 field size. They have also shown that without 
applying the skin dose correction factors, the skin dose estimate based on a single 





Clinically, Roland et al. determined the skin dose by EBT Gafchromic films for 
prostate and head-and-neck patients on three IMRT delivery systems (serial, helical 
TomoTherapy, and step and shoot IMRT system). Roland et al. showed that the 
Gafchromic films quantify average skin dose to within 10 % of the values measured 
by the ultra-thin TLDs for all the IMRT delivery systems [52]. 
2.6.4 MOSFET dosimeter 
Metal Oxide Semiconductor Field-Effect Transistors (MOSFETs) (Figure 2-5) have 
been used in clinical radiation dosimetry due to their advantageous properties. The 
major features of MOSFETs are their extremely small physical size, immediate 
readout, on-line readout system, high spatial resolution, reusability, and the ability to 
record dose history and offer real-time dose information. Their compact 
constructions enable them to be used on any surface and do not involve a connection 
to a high voltage terminal. Furthermore, MOSFETs have good sensitivity, 
reproducibility, and stability with minimal temperature effects [5, 78, 93, 95, 100]. 
In contrast, MOSFET dosimeters have some downside which should be considered.  
They are known to exhibit an energy dependent response when irradiated in free air 
geometry at energies below 250 – 280 keV, an angular dependent response, 
temperature dependence during threshold voltage readout, and variations in the 
thickness of the build-up material between different MOSFETs. Moreover, 
MOSFETs have a finite lifetime which is proportional to the bias voltage applied. 
The principal operation of MOSFET dosimetry is based on the generation of hole–
electron pairs in the oxide of MOSFET structure (gate oxide) due to ionizing 
radiation. The energy required to produce one e – h pair in silicon oxide is about 18 




are captured on traps and create a positive build-up charge QT. The positive charge 
sheet formed effectively changes the current in the channel of MOSFET and leads to 
corresponding change of the gate bias voltage Vth (i.e. a shift in the threshold 
voltage) to ensure a given constant current flow through the channel. The current in 
the channel is very sensitive to the charge QT as it is physically located very close to 
the channel. The shift of Vth is a measure of an absorbed dose in the gate oxide 
(SiO2)
 measured the amount of radiation absorbed by MOSFET before and after 
irradiation [93].  
The MOSFET readout system has the ability to read out multiple MOSFET 
dosimeters with excellent spatial resolution (~1μm) and temperature stability, 
minimal slow border trapping effects and dose-rate independent. 
Many of studies have shown that commercially available MOSFETs would be ideal 
for in vivo skin dosimetry, a vital device in many radiation therapy applications 
including medical LINAC, IMRT, MRT, hadron therapy and brachytherapy. 
Rosenfeld (2002) concluded that there was a good agreement between Attix 
chamber, TLD and MOSFET in percentage of surface dose relative to dmax, which 
was better than 1 % [93]. 
Kinhikar et al. estimated the skin dose using MOSFET and TLD placed inside the 
mask for Head and Neck patients treated with IMRT using TomoTherapy planning 
system and then compared the measured skin dose with TPS. It was concluded that 
the variation between skin dose measured with the MOSFET and the TLD was about 
2.2 %.  Moreover, it was concluded that MOSFETs can be used as an applicable 
dosimeter for measuring skin dose in high dose gradient where the treatment 




measured patient skin doses had good reproducibility, with inter- fraction deviations 
ranging from 1 % to 1.4 %  [78]. 
Xiang et al. results showed that the micro-MOSFET has a water-equivalence 
thickness (WET) of 0.87 mm for 6 MV beam and 0.99 mm for 10 MV beam from the 
flat side, and a WET of 0.72 mm for 6 MV beam and 0.76 mm for 10 MV beam from 
the epoxy side. They concluded that the micro-MOSFET is an effective and efficient 
dosimeter for measuring skin dose; because this dosimeter can provide superficial 
dose measurement at surface with an accuracy of ± 6 % for both normal and oblique 
incident beams, in comparison with Monte Carlo calculations. In addition, for 
measurements at deeper depths beyond the build-up region, one can expect a better 
accuracy of ± 3 – 5 %. This feature enables micro-MOSFET to measure doses at 
different depths and to monitor the dose to skin tissues under 1– 2 cm bolus material, 
such as those used in radiation treatment of breast cancer [85]. However 
commercially available MOSFET system is not able to measure skin dose at WED 
0.07 mm as clear from above.  
2.6.5 MOSkinTM dosimeter 
The Centre for Medical Radiation Physics (CMRP), University of Wollongong 
(UoW), Australia, recently designed clinical MOSFET dosimetry system, which 
consists of miniature MOSFET dosimeter, known as MOSkinTM and a 
microprocessor-based reader [5, 84], Figure 2-6. Many works have been done to 
investigate the properties of MOSkinTM and they concluded that the MOSkinTM is a 
suitable tool for surface dose and build-up region dosimetry and it is accurate and 
reliable dosimeter to determine the skin dose in clinic in megavoltage external 




for routine IMRT QA and in vivo skin dosimetry [5]. The newly developed 
MOSkinTM dosimeter, which is encapsulated into a thin water protective film, has a 
minimal reproducible intrinsic build-up recommended for skin dosimetry [5]. The 
main advantage of the MOSkinTM dosimeter is its ability to provide  water equivalent 
depth of measurement at a depth of 0.07 mm [4] as recommended by the ICRP for 
skin dosimetry [66], making it a suitable dosimeter for measuring skin dose in real-
time during treatment.  
MOSkinTM small physical size with submicron dosimetric volume which provides 
excellent dosimetry spatial resolution for depth dose measurements where a steep 
dose gradient exit [5]. It is a waterproof [6], reusable, with high sensitivity, and 
allows the permanent storage of dose. In addition, the MOSkinTM can provide 
immediate readout without deterioration of information, and it has a negligible 
radiation field perturbation owing to their small size and ease of use [5]. It is also 
possible to optimise the sensitivity and the reproducibility by choosing sensors with 
different oxide thicknesses and varying the bias-supply voltage [89].  
The readout process of MOSkinTM requires measurement of the voltage across the 
gate under the condition of the constant source – drain current, called the threshold 
voltage (Vth). The Vth increases with accumulated radiation dose. The readout current 
corresponds to the thermo stable point of the MOSFET to avoid errors associated 
with thermal instability of the Vth. The sensitivity of the MOSkin
TM dosimeter is 





Figure 2-5  Photograph of Clinical Semiconductor Dosimetry System reader attached 
to one MOSkinTM probe. 
 
Due to its considerable advantages, several authors confirmed that the MOSkinTM is a 
good tool to be used for in vivo skin dosimetry [84, 89, 94]. Jong et al. investigated 
the response of the MOSkinTM dosimeter under different treatment factors such as 
SSD, wedges, field sizes, and angle incidents. Their results showed that the 
MOSkinTM response has an excellent reproducibility of less than 1 % and linearity 
(R² = 0.997) for the dose range of 0 cGy to 300 cGy with average sensitivity of 2.53 
± 0.03 mV/cGy for 6 MV photon beam. The response of MOSkinTM to different 
SSDs, field sizes, surface, radiation incident angles, and wedges was found 
reasonable. The average variation of all SSDs (80 - 110 cm) was 0.1 % for the 
MOSkinTM, 1.0 % Gafchromic EBT 2 film and 0.5 % for Markus ionization chamber. 
Their results showed that, the MOSkinTM measurements were in good agreement 
with EBT 2 film for field size < 25× 25 cm2 whereas, for field size > 25 × 25 cm2, 
the MOSkinTM dosimeter and Markus ionization chamber measurements showed an 
enhanced response, compared to the Gafchromic EBT 2 film. This may be due to the 




MOSkinTM dosimeter. The response of MOSkinTM detectors were greater by 1.01 % 
in 6 MV photon beam compared to 10 MV photon beam and that is due to the skin 
sparing effect of 10 MV photon. The average variations of MOSkinTM measurement 
with Markus ionization measurement was -5.5 % and 5.1 % for physical wedge and 
dynamic wedge, respectively. The surface dose measured for oblique beams with the 
MOSkinTM increased up to 1.95 times of that of normal beam incidence for example 
Gafchromic EBT 2 film, the MOSkinTM detector in the face-up orientation showed 
angular independence. However, when the MOSkinTM with the face-down orientation 
was used, surface dose measurement showed a trend of over-response when 
compared with MOSkinTM detector with face-up orientation and Gafchromic EBT 2 
film [89]. 
Kwan et al. investigated the suitability of MOSkinTM for surface dosimetry on a 
rectum wall during HDR prostate brachytherapy and compared the results with 
RadFET, and the Attix chamber. It was reported that for 6 MV and 10 × 10 cm2 
photon beam at an angle of normal incidence, the percentage skin dose was 20.4 % 
and 36.3 % measured by MOSkinTM and the RadFET detector, respectively. The 
response of the MOSkinTM was in good agreement with the Attix chamber results. 
Kwan et al. concluded that, the new design of the MOSkinTM dosimeter has superior 
performance in skin dosimetry when delivering dose using MV x-ray beams from a 
LINAC when compared to the commercially available RadFETTM. The MOSkinTM 
dosimeter does not have a significant angular dependence; it achieved a uniform 
angular response to within ± 2 % when irradiated in a solid water phantom at 
irradiation angles of ± 300, ± 600 and ± 750, using field sizes from 5 × 5 to 40 × 40 
cm2, even when irradiated from the underside of the detector [95]. Zhen-Yu Qi et al. 




system in patient-specific QA of s-TomoTherapy for head and neck cancer patients. 
It was reported that the impact of SSD on the newly developed MOSFET was 
minimal, it was ≤ 0.4 %. For 6 MV photon beam, the deviations from 100 cm SSD 
were about 0.2 % for the SSD of 110 cm and 0.4 % for 90 cm SSD. The field size 
dependence of MOSkinTM detector varied by less than 2.5 % over all photon field 
sizes and by less than 1.0 % for field sizes smaller than 20 × 20 cm2, which are 
usually included in IMRT fields for NPC treatments. The developed MOSkinTM 
dosimeter displayed a uniform angular isotropy within 2 % over 3600.  The results of 
the PDD measurement differences between MOSkinTM dosimeters and ion chambers 
were within 2.5 % for depths up to 15.5 cm and within 3.5 % for depths of 16.5 to 
19.5 cm, respectively. They did not find significant difference between MOSkinTM 
dosimeter and ion chamber detectors (ρ > 0.05). The mean percentage ± standard 
deviation between MOSkinTM measurements and treatment planning system 
calculations at the target region for eight s-TomoTherapy plans was 0.77 % ± 1.50 
%, while the mean deviation between 0.6 cm3 ion chamber measurements and 
treatment planning system calculations was 0.54 % ± 1.56 %. Additionally, the mean 
dose deviation measured in the relatively high-dose gradient region by the MOSkinTM 
dosimeter was 1.34 ± 1.86 %, while it was 1.77 ± 2.51 % as measured by the 0.125 
cm3 ion chamber. Comparing to ion chamber, the MOSkinTM dosimeter might be 
more suitable for measurement with a steeper dose gradient. MOSkinTM system 
measurements and ion chamber measurements agreed at all points in IMRT phantom 
plan verification, within 5 %. The average difference between the measured and the 
planned doses for 48 in vivo verification measurements for 8 NPC patients was 3.33 
% and ranged from -2.20 % to 7.89 %. A deviation of less than 5 % from the planned 




MOSkinTM dosimeter is a good candidate for IMRT dose assessment not only in the 
homogeneous area but also in the rapid-dose fall-off region [84]. 
Kelly et al. measured the skin dose in the presence of the thermoplastic 
immobilization casts (Orfit) for a clinical conformal and IMRT breast plan using the 
radiochromic film and MOSkinTM dosimeters at a range of water equivalent depths 
representative of the different skin layers. It was concluded that there was good 
agreement between the film and MOSkinTM; however, The MOSkinTM measured 
doses were slightly less than that measured by the film [41]. 
Rosenfeld et al. have introduced the MOSkinTM detector based on a MOSFET which 
utilises a special drop in packaging to allow reproducible measurements of skin dose 
at the WED of 0.07 mm. Further studies demonstrated that the MOSkinTM is a 
suitable device for in vivo skin dosimetry in many radiation therapy applications, 
both on a medical LINAC [5, 41, 43, 68, 101] and in brachytherapy [95, 102]. 
Previous studies have reported using the MOSkinTM dosimeter for real-time in vivo 
skin dosimetry in head and neck IMRT [5], TomoTherapy [84] and for breast 
radiation therapy [41]. These studies showed the reliability and feasibility of using 
the MOSkinTM as an in vivo dosimeter in megavoltage radiation therapy for surface 
dosimetry. 
2.6.6   Silicon diode dosimetry 
Silicon diode dosimeters have been used widely in medical radiation dosimetry. A 
silicon diode is basically a p-n junction. Using doping of silicon with different 
impurities (e.g. phosphorous and boron) it is possible to create two regions: the first 
region contains positive charge carriers (holes) and it is called a p-type and the 




The operation principle for a silicon diode dosimeter is demonstrated in Figure 2-7. 
When the n-type and p-type materials are attached together, the majority carriers of 
each side diffuse to the opposite side at the p-n junction. This results in an electrical 
filed, called build-in potential Ψ0, which prevents further diffusion of the majority 
carriers. Under the effect of Ψ0 at the p-n junction, the electrons from n-type region 
get attracted to the p-type region, filling the holes at the junction. This means that 
there are no available charge carries in this region. Hence this area which is depleted 
of charge carriers is known as the depletion layer, W. 
When the diode operates in passive mode (i.e. no external bias voltage is applied), no 
current flows in the external circuit. When ionizing radiation traverses the diode, it 
generates electron-hole pairs in the diode. The excess minority carriers (i.e. electrons 
in the p-side and holes in n-side) located within the diffusion lengths, Ln and Lp, will 
diffuse towards the p-n junction and be swept by the build-in potential towards the 
electrodes. This flow of charge results in a current flow in the external circuit, which 
is measurable by the electrometer [103]. 
 




Diode dosimeters have been used in high energy photon beam and electron beam 
dosimetry since 1960s [104, 105] and as an in vivo dosimeter for the radiation 
therapy application since the early 1980s [106]. Several studies have been done for 
diodes to be used for the dosimetry of photon beams [107-110]. However, only a 
limited number of publications studied their use for electron beams [111-113]. 
Silicon diode dosimeters are suitable for quality assurance applications and in vivo 
dose measurements because of their sensitivity relative to the ionisation volume is 
high (about 18,000 times higher than for an air-filled ionisation chamber [114], ten 
times less than those required to ionise air). Thus, the sensitive volume can be small 
and specific and the effective measuring point can be placed less than 1 mm below 
the outer surface of the dosimeter, leading to a good spatial resolution without 
compromising sensitivity. Other features, which makes diode a good candidate for 
radiation therapy application is that silicon diode is almost independent of the 
stopping power ratio in comparison to water in the MV range of energy but show 
larger attenuation in the photon energy range from 5 to 300 keV (large discrepancy 
in the mass absorption coefficient ratio between silicon and water largely due to the 
photoelectric effect). Other advantages of the silicon diodes are real-time feedback 
(compared to film), high linearity, radiation hardness and a small size (compared to 
ionisation chambers), do not need external bias, excellent reproducibility, and its 
ability to be used in passive mode [115]. Moreover, diodes show fast charge 
collection due to high mobility, and a long mean free path of charge carriers. 
However, silicon diodes have their own limitations compared to the other types of 
dosimeters e.g. silicon diodes over-respond at low photon energy (˂ 150 KeV) due to 
the increased photoelectric cross section [115]. Furthermore, current designs of 




conditions for MV field of interest, do not make them suitable for direct skin 
dosimetry on medical LINACs [116]. The angular, energy, temperature and dose rate 
dependency need a strict characterization [117]. The doping level affects the 
response of the diode in terms of accumulated dose, dose rate, and temperature 
dependency [118].  
Recently, silicon planar arrays are vastly used in IMRT quality assurance, such as the 
Sun Nuclear MapCHECK and ScanDos Delta4 bi-planar system.  
2.7   Conclusion 
Breast cancer is a main health problem throughout the world and it is the major cause 
of death from cancer among female worldwide. Currently, it is the most female 
common cancer globally and it is the second cancer after the lung.  One in ten of all 
new cancers diagnosed annually in both developed and developing countries is a 
cancer of the women breast. Radiation therapy plays a major part in the management 
of breast cancer. Many works reported that radiation therapy results in both enhanced 
survival rates and increased local control of the cancer. Recently, there are several in 
vivo skin dosimeters are used to measure the skin dose. The main difficulty in 
accurate skin dosimetry with the current in vivo dosimeters are: 1) their ability to 
measure dose at small WED, 2) to have an extremely thin dosimetric volume to 
enable measurement of the dose in a radiation fields, often with a high dose gradient 
at the media interface. Due to its desirable features, such as the ability to perform 
measurements in real-time and provide WED of 0.07 mm, silicon dosimeter 
technology, such as silicon diode and MOSkinTM, has the potential to be used as 





3 Chapter 3 Material 
This chapter describes the dosimeters system that were used in this thesis and the 
working principles of their electronic readout system. The dosimeters which were 
used in this project were the newly developed n-type skin silicon diode and 
MOSkinTM dosimeters. The advanced Markus ionization chamber, Attix ionization 
chamber and the film dosimetry were used as the comparison dosimeters in chapters 
of this thesis. Additionally, the properties and composition of brass mesh bolus 
characterised in chapter 6 and 7 of this thesis will also be briefly described.  
3.1   n-type Skin Diode Dosimeter Overview 
The strong response of a silicon device to ionising radiation and their capability to 
measure integrated dose was discovered in the late 1960s and the idea openly 
published in 1974 [119].  
3.1.1 Design and Fabrication 
The newly developed Skin diode dosimeter used in this study is n- type silicon 
epitaxial Skin diode dosimeter which is designed and developed at Centre for 
Medical Radiation Physics (CMRP), University of Wollongong (UoW), Australia, 
and fabricated at the CMRP exclusive Microelectronic foundry SPA-BIT (Ukraine). 
The n-type epitaxial Skin diode has a die size of 1 × 1 mm2 cross section, and 0.5 × 
0.5 mm2 for the sensitive area, which is defined by boron ion implanted junction. The 
dosimeter structure is manufactured on a 7 μm (100 Ω.cm) thick n-type low 
resistivity silicon epitaxial layer grown onto a low resistivity (0.001 Ω.cm) 380 μm 
thick n+ silicon substrate. In the prototype design of this epitaxial dosimeter, a 




importance of the SiO2 is to allow selective implantation of the n
+ region and to act 
as a passivation layer for the silicon diode. The epitaxial diode was manufactured 
without guard ring. The p+ and n+ regions are covered with evaporated 0.7 μm thick 
Al layer partially overplay silicon oxide to provide reliable ohmic contact. The 
schematic diagram of n-type silicon Skin diode structure is represented in Figure 3-1.  
 
 
Figure 3-1 Simplified schematic of n-type silicon Skin diode (epitaxial) structure. 
Illustration not to scale. 
 
The advantage of using an epitaxial layer in radiation dosimeters is that the sensitive 
volume is limited via the thickness of several microns epitaxial layer providing 




effect of variation of the diffusion length of charge carrier  due to  radiation damage, 
which is experienced in conventional bulk silicon dosimeters [120]. The Skin diode 
is configured to operate in a passive mode, that is zero external bias is applied 
between the n+ and p+ junction, in order to avoid the leakage current.  
3.1.2 Dosimeter Packaging  
The die of the Skin Diode dosimeter was assembled onto a thin Kapton polyamide 
pigtail via using a special technique called drop-in technique. The thin Kapton pigtail 
has density of 1.42 g cm-3 with pigtail thickness 0.6 mm, width 10 mm and 320 mm 
length as shown in Figure 3-2 and an effective atomic number, Zeff. = 6.6. This is 
more tissue-equivalent than ceramic (Al2O3 Zeff. = 11.2) and expected to create less 
perturbation to the radiation beam [121].  
The “drop-in” radiation sensors packaging technique was developed at CMRP. This 
technology minimises energy dependence and dose enhancement effect in a photon 
field due to avoiding high Z materials that are typically used to package silicon dies. 
It also provides reproducible WED of dose measurement and reduces intrinsic an 
angular dependence associated with packaging [122], as shown in Figure 3-2. The 
drop-in technology consists on assembling the dosimeter on a flexible carrier from 
which the dosimeter dies hangs down [122, 123]. 
 
Figure 3-2 Silicon Skin diode Kapton probe. 
 
The kapton pigtail of the Skin diode probe has built in an internal thin metal 




3.2  TERA Readout System 
In this thesis the TERA readout system, shown in Figure 3-3, is used to readout the 
current signal from radiation detectors such as Skin diode dosimeter. TERA, shown 
schematically in Figure 3-4, is a multichannel charge-to-frequency converter, 
designed by the National Institute for Nuclear Physics (INFN), Turin Division, Italy, 
and the University of Turin microelectronics group [124, 125]. TERA chip is an 
Application-Specific Integration Circuit (ASIC) originally designed to readout pixel 
and strip detectors for hadron therapy [126]. It has originally been implemented in 
2D and 3D Magic Cube and a pixel ionization detector [124]. The latest family of 
ASIC is called TERA06, which has been designed in CMOS 0.8 µm technology and 
has been developed to independently read out the current from up to 64 pixels or 
strips and convert it to frequency [125]. TERA06 has been employed by CMRP 
firstly for DMG detectors and later by Scanditronix - Wellhöfer (IBA-group) in 
commercial dosimeters used in radiation therapy. 
 





Figure 3-4 Schematic diagram of TERA readout. 
3.2.1 TERA functionality  
The TERA system as mentioned above, is the current-to-frequency converter 
followed by digital counter. It has been implemented with the charge balancing 
integration technique [125]. The work of TERA system has been reported in several 
articles [124-127].  The most important features of TERA06 are summarised in Table 
3-1.  
Table 3-1 TERA 06 Main features [128]. 
Technology CMOS 0.8 μm 
Die size 6 mm × 7 mm 
Number of channels 64 
Max clock frequency 20 MHz 
Input current Unipolar 
Latch Dead time free readout 
Max I-f converter frequency 5 MHz 
Non-Linearity < 1 % 
 
When an incident radiation beam impinges on the Skin diode dosimeter, the electron-
hole pairs will be generated in the silicon and thus these moving charge carriers 




current (Iin) is integrated over a capacitor (Cint) of 600 fF via an Operational Trans-
Conductance Amplifier (OTA). The integration output waveform from the OTA 
appears as a voltage ramp (VA).   The VA is compared with a threshold voltage (Vth) 
by a synchronous comparator. When VA ˃ Vth, a fixed amount of charge (called 
charge quantum, Qc, which is a unit charge needed for 1 count) is subtracted from the 
capacitor Cint. This results in sharp decrease of the voltage across Cint, which is 
proportional to the charge injected by the subtraction circuit. After this charge 
subtraction, the output of the OTA (VA) ramps up again, and the process is repeated, 
thus giving a saw tooth waveform [124]. For each charge subtraction, a pulse is also 
sent to the digital counter. Therefore, the frequency of the pulse is proportional to the 
input current, according to the following relation:  
f = Iin/Qc       Equation 3-1 
where Iin is the input current and, Qc is the charge quantum. 
Therefore, the number of pulses generated in the measurement time multiplied by the 
charge quantum gives the total charge read-out from the input. Figure 3-5 shows the 
typical behaviour of the voltages at the output nodes of the OTA, the comparator and 
the pulse generator. 
 
Figure 3-5 Waveforms at the nodes of the converter. VA is a voltage ramp, which has 





The charge quantum (Qc) is obtained by sending a voltage pulse from the Pulse 
generator (PG) to the 200 fF capacitor (called subtraction capacitor, Csub) included in 
the Subtraction circuit block. Therefore, the charge quantum is defined by the 
relation: 
Qc = CsubVsub  Equation 3-2 
where Vsub is defined as the difference between two reference voltages (Vpulse+ and 
Vpulse_), which are set externally in a range between 0.5 and 4.5 V. In this thesis, Qc = 
100.40 fC. 
A voltage variation Vsub across the subtraction capacitor Csub corresponding to a 
voltage variation of  
ΔV = VsubCsub/Cint  Equation 3-3 
across the integration capacitor Cint. 
The voltage variation ΔV is applied at the input of the comparator and must be able 
to reduce the output of the OTA resetting the status of the comparator. The minimum 
charge quantum is set by the resolution of the comparator and is limited in the 
present design to 100 fC. 





Figure 3-6 Architecture of the 64-channel charge measurement ASIC. 
 
The following signals can be externally set and are common to all channels: OTA 
reference voltage (Vref), comparator thresholds (Vth), Vpulse+ and Vpulse-. 
The counters can be zeroed via a common asynchronous digital input, reset. The 
read-out of the counters can be done independently with respect to any other 
operations. Asserting the latch, the actual bit configuration of each 16-bit counter is 
stored in a 16-bit register. This operation is performed in parallel for all the 64 
channels. Any given channel can be acquired by addressing it via the six digital 
inputs (channel select lines).  
Using a pulsed LINAC radiation beam, the beam generates a pulse in a detector 
corresponding to a high current of approximately 7 μA within a very short pulse 
width of 3.5 μs. The pulse period may range from 16 ms to 2.7 ms, in the case of 100 
to 600 MU/min repetition dose rate. Within the initial pulse width of 3.5 μs, the high 




case, it is impossible to bring the charge below the threshold value with a single 
charge quantum, Qc, pulse. Thus, the pulse generator (PG) will continue run at a 
maximum speed, to issue pulses to the subtraction circuit until the overload is 
removed. Since the LINAC pulses have the advantage of having a long period (1.6 to 
2.7 ms), which means the subtraction circuit has sufficient time to remove the 
overload before reaching the next pulse, it is important to ensure that the input 
current generating voltage on the capacitor does not go above the positive rail 
voltage. If this occurs, the output counts will be saturated and the generation of 
counts will be constant in that case, even if the input current increases. Naturally, 
setting the Qc to a high value enables subtraction of the input current to occur at a 
faster rate. This is created at the expense of a lower sensitivity of the counts 
generated. 
3.2.2 Data Acquisition System (DAQ)  
The DAQ and software, which is associated with TERA system collects and analyses 
the data. This software was originally developed by the CMRP. The DAQ allows 
offline and online data analysis. The DAQ used for the skin silicon diode employs 
one TERA chip, containing 64 independent channels. In this work, only one channel 
was used to readout a single Skin diode. This DAQ software allows the user to 
produce graphical presentation of the real-time response of the detectors through the 
software named Rad-X Dose View.  
3.3   MOSkinTM Dosimeter 
The MOSkinTM is a dosimetry probe based on the MOSFET. It is designed 
successfully by the Centre for Medical Radiation Physics (CMRP) at University of 




a p-MOSFET dye  with submicron thickness of the sensitive volume embedded into 
Kapton pigtail strip with thickness of 0.55 mm [129] with a width of 3 mm and 
length about 35 cm that allow electrical connections to the silicon chip. The entire 
dye is approximately 350 μm thick, which is encapsulated into Kapton tail providing 
a thin reproducible water-protective package (film) above the silicon dye.  
The MOSkinTM has a 0.55 μm thick gate oxide, allowing for high special resolution 
measurement, and sealed with 70 μm thick water equivalent, flexible polyamide film 
of highly reproducible thickness [94]. This thin film carrier acts as an encapsulating 
layer that protect the silicon chip from the damage which caused by the moisture and 
also provides electrical connections to the MOSFET chip. Additionally, the film acts 
as thin build-up, with an effective depth of approximately 0.07 mm [130].  
Special packaging technology described above, known as ‘drop in” sensor packaging 
was developed at UoW, providing a highly reproducible water equivalent depth 
(WED) of approximately 0.07mm, that is the ICRP recommended thickness for the 
skin measurement [89, 94, 129].  
In this thesis, the MOSkinTM dosimeter was used in an active mode with a high 
sensitivity bias supply of +15 V to increase the sensitivity and linearity of its 
dosimetric characteristics. This corresponds to a sensitivity of approximately 2.5 mV 
cGy−1 for measurements at a depth of 1.5 cm in the water phantom under a 6 MV 
photon beam from a medical LINAC. 
 





In the current work, the sensitivity of MOSkinTM was studied by taking the 
recalibration factors which were measured at the end of each experiment. 
Jong et al. studied the sensitivity of the MOSkinTM dosimeters, and they concluded 
that the sensitivity of MOSkinTM decreases as the cumulative dose increases, 
9×103 mV/cGy decreasing sensitivity per 1 Gy. Therefore, it is recommended the 
periodic recalibration be carried out throughout the dosimeter’s useful lifetime based 
on the accuracy needed [75]. 
3.4   MOSkinTM Readout system 
Clinical Semiconductor Dosimetry Systems reader (CSDS), is a custom-built 
portable, battery- powered MOSkinTM reader, which was designed by CMRP at UoW 
Australia, shown in Figure 2-6. MOSkinTM dosimeter has microprocessor-based 
reader which is connected to the laptop provided with specified software. Each 
individual MOSkinTM probe is connected to the reader via a cable. Five dual sensor 
MOSkinTM probes can be attached to the reader altogether, enabling five low-
sensitivity and five high sensitivity MOSkinTM sensors to be readout during 
irradiation simultaneously. The connection to the reader applies a bias voltage of 3 - 
16 volts to each MOSkinTM probe. A measurement is made by recording the threshold 
voltage pre-irradiation then again post irradiation; the radiation dose received is 
proportional to the change in threshold voltage. The capability of the reader is to 
measure Vth within ± 1mV. In all clinical studies, the high sensitivity bias (+ 15 V) 
setting is selected to increase the sensitivity of the MOSkinTM dosimeter and the 
linearity of its response.  
There are two readout systems used in this thesis, the CSDS and the new and 




a computerised reader, which was developed in-house (CMRP), UoW, Australia. The 
MOSkinTM dosimeter has microprocessor-based wireless reader utilising RF or 
Bluetooth connection to the laptop provided with specified software. The computer 
data acquisition system measures periodically the instantaneous voltage signal with a 
user defined frequency of 1 Hz. The in- house developed software permits for the 
online graphical representation of the change in the threshold voltage (proportional to 
accumulated dose) or increments in the threshold voltage for consecutive readouts 
(proportional to dose rate). This software converts the voltage to dose and display the 
cumulative dose delivered to the MOSkinTM as treatment progress. The acquisition of 
data points can be defined in the control software by the user for time intervals of 
less than 1 s, thus providing a real-time dosimetry system for in vivo measurements. 
The stated uncertainty associated with this reading equipment is lower than ± 0.125 
mV  [90]. The wireless MOSkinTM read-out system is temperature independent, small 
in size, battery operated and it does not require cabling. Particularly advantageous of 
MOSkinTM is that it is an on-line read out dosimeter, which allows to display the dose 
with time during the treatment delivery and to determine the contribution of each 
individual arc or field to the total dose distribution.  Additionally, wireless reader 
provides design making the MOSkin probes temperature independent that reduce 
possible error associate with temperature changing during measurements.  
3.4.1. MOSkinTM Calibration 
MOSkinTM probes were placed on the 30 × 30 × 5 cm3 slab water phantom and 
aligned to isocenter at once using room laser alignment and placed at the depth of 
dose maximum (dmax), 1.5 cm of solid water for 6 MV photon beam, with a 100 cm 




gantry angle of 0° and field size of 10 × 10 cm2 were selected. The MOSkinTM probe 
was placed in groove accurately matching the probes produced in a slab phantom. 
The importance of this groove is to allow an accurate positioning of the dosimeters at 
the geometric centre of the radiation field and the levelling of the probe surface with 
the phantom surface and avoid an air gap if additional build up is placed on the top of 
the dosimeters. In order to reduce the effect of temperature dependence of the 
dosimeters and get an accurate reading, the MOSkinTM probes were placed on the 
phantom for approximately 60 second before delivering any radiation to reach the 
thermal equilibrium (it was not required for newly wireless reader). The reading of 
the MOSkinTM dosimeter was recorded before and after each irradiation and the 
change of the threshold voltage calculated as Δ Vth1 = (Vth1- Vth0). The measurements 
were performed on two LINACs, such as Varian Clinac 21EX Linear accelerator 
(Varian Medical Systems, Palo Alto, CA) and a Varian TrueBeam (Varian Medical 
System, Palo Alto, CA, USA) linear accelerator. The calibration was performed by 
delivering 40 cGy (to save their lifetime while keeping a reasonable signal) to the 
MOSkinTM probes in three separate irradiations.  
A calibration factor, CF (mV/cGy) was acquired by dividing the average threshold 
voltage shift ΔVth (mV) by the delivered dose (cGy), in this work the delivered dose 




                    Equation 3-4 
For the wireless MOSkinTM system, set number 2, the CF was calculated as  
CF = initial CF – 0.085 × ΔVth Equation 3-5 
where 0.085 represents the average of the (Δ CFi / ΔVi) that consider degradation of 




For calibration of both dosimeters, the measurements were repeated three times and 
then the average reading used for analysis. 
3.5   Film Dosimetry 
Gafchromic film has been used widely as skin dosimeter in radiation therapy due to 
its several advantageous features for dosimetry, such as its high planar spatial 
resolution, low spectral sensitivity, tissue equivalency, large dynamic range (10-2- 
106 Gy), low energy independence, insensitivity to visible light and self-development 
[49, 71] . Radiochromic film is light weight so it can be bent and cut to any size or 
shape to be used clinically and it can be used in the dose range from 10 to 100 Gy. 
For both film types, careful and proper handling of the film is significant to ensure 
the correct and consistent readout. The Gafchromic EBT film was initially used in 
radiation therapy in 2004. International Specialty Products (ISP, Wayne, NJ) released 
a new film generation, Gafchromic EBT 3 film in 2011 [73].  
Recently, the new generation of Gafchromic films, EBT 3, has become available and 
popular tool to verify dose distributions in highly conformal radiation therapy such 
as IMRT. Several studies have shown that the EBT 3 has the same composition and 
thickness of the sensitive layer of the EBT 2 films, but the orientation dependence 
with respect to film side and anti-Newton ring artifacts coating are eliminated in EBT 
3 films [73]. 
3.5.1 EBT 3 Gafchromic Film 
Gafchromic EBT 3 radiochromic dosimetry film is comprised of a single active 
layer, nominally 27 μm thick, containing the active component, marker dye, 
stabilisers, and other additives giving the film its low-energy dependence. The 




RGB film scanner, enables all the benefits of multichannel dosimetry. The active 
layer is sandwiched between two, 120 μm transparent polyester substrates; this 
symmetric structure eliminates the need for keeping track of which side of the film is 
facing the light source of the scanner, Figure 3-8. The polyester substrate has a 
special surface treatment containing microscopic silica particles that maintain a gap 
between the film surface and the glass window in a flatbed scanner [73, 131]. 
Moreover, the EBT 3 film is more sensitive than the older versions of radiochromic 
film with its wide dose range from 1 cGy to 40 Gy. The effective point of 
measurement for the EBT 3 film was defined at 0.153 mm depth [71, 131]. 
 
Figure 3-8 Gafchromic EBT 3 Film layer arrangement. 
 
Several authors studied the characteristics of EBT 3 films and investigated the 
application of EBT 3 in clinical practice.  
Casanova Borca et al. studied the characteristics of EBT 3 films and investigated the 
application of EBT 3 in IMRT. They reported in their study that most of the 
characteristics of EBT 3 film are similar to the EBT 2 film. The EBT 3 film, showed 
a difference up to 4.5 % response between portrait and landscape orientation, 




one should not to mix films acquired in portrait orientation with those acquired in 
landscape. 
On the other hand, the differences from film face-up versus facedown scan 
orientation were negligible, with values less than 0.7 % for doses up to 4 Gy, thus the 
orientation dependence with respect to film side is insignificant. The dose response 
curves showed that the EBT 3 can work up to nearly 40 Gy without a problem and 
the result of varying the energy level and dose rate showed response is nearly not 
significant of radiation energy used in IMRT treatments, the differences between 
EBT 3 and EBT 2 films were negligible with values less than 1 % for doses up to 4 
Gy.  The variations in netOD between 24 h and 72 h after irradiation were less than 
0.005 for all doses studied. Additionally, the study of the colorization process 
showed a fast stabilization of the film within two hours. Measurements of EBT 3 
films showed good agreement with the TPS calculations, with averaged fractions of 
passed Γ values greater than 99 % and  97 % using 4 % – 3 mm and 3 % – 3 mm 
gamma evaluation criteria, respectively, which are generally used in IMRT DQA 
applications [73]. 
3.5.2 EBT 3 Gafchromic Film preparation and scanning 
The Gafchromic EBT 3 film (Ashland ISP Advanced Materials, USA) from the same 
lot batch no. 05181502 was used in all measurements in this thesis. The nominal size 
of this film was 20.3 × 25.4 cm2. The film was cut into pieces of 3 × 3 cm2 
dimension.  The Gafchromic EBT 3 film was pre-irradiation scanned and post-
irradiation scanned using a 48 - bit RGB (Red-Green-Blue) transmission film 
scanner, the EPSON 10000XL Photo Flatbed Scanner (Epson America, Inc., Long 




corrections were applied. Attention was made when EBT 3 film was placed and 
orientated in the scanner, that is in order to keep all pieces of film in same position 
and orientation for consistency and thus reduce the systemic errors. The EBT 3 film 
was placed at the centre of the scanner, which was done by the aid of a 3 × 3 cm2 
positioning frame or cardboard template, so that every piece of film was scanned at 
the same scanner position in order to minimise the effect of the lateral dependence 
artifacts, which is the non-uniform response of the readout due to the light scattering 
of the scanner lamp caused by particles in the film active layer [73]. The orientation 
of the film in the scanner was kept as landscape orientation. The digitised image was 
saved as Tagged Image File Format (TIFF).  Each EBT 3 film piece was pre-scanned 
for six times to ensure a proper scanner warm up and to stabilise the performance of 
the scanner and to achieve consistency analysis, but the last three film scanning were 
used for analysis. After approximately 48 hours had passed between film irradiation 
and post-scanning, the irradiated pieces of film were post- scanned and the image 
files were measured using ImageJ Software (IMAGEJ) (version 1.47v).  
Tsang Cheung et al. investigated the post-irradiation colouration effects of 
Gafchromic EBT film and found that this type of film produces a post-irradiation 
colouration effect of approximately 9 % – 11 % which mostly occurs within the first 
6 h [87]. Each film was separated into blue, green, and red channels. The data was 
taken from the red channel only, as this corresponds closely to the maxima on the 
absorption curve for Gafchromic films, achieving greatest scan sensitivity [71, 73, 
131]. To get the average background intensity (I0) and average intensity (I) values by 
using IMAGEJ, a square region of interest (ROI) was created on the centre of the 




Optical Density (netOD) was determined for a piece of film exposed to a dose Di 
through the following formula, according to the definition of Devic et al.[74, 132]: 
𝑛𝑒𝑡𝑂𝐷(𝐷𝑖) =  log10(
𝐼0
𝐼(𝐷𝑖)
)           Equation 3-4 
The background intensity (I0) and intensity (I) values are measured from image pixel 
values of the film scan with related statistical errors σI and σI0, respectively; standard 
deviations are calculated across three image data sets (3 different films irradiated to 
same conditions). 















           Equation 3-5 
Where 𝜎𝐼0 and 𝜎𝐼(𝐷𝑖) are the standard deviation of the pixel value of the pre-scan film 
and post-irradiated film, respectively [74, 132]. 
The 2nd order polynomial was used to fit the net optical density to absorbed dose D 
(cGy), as outlined in Devic et al. [74, 132] by 
𝐷𝑓𝑖𝑡 = 𝑎 ×  𝑛𝑒𝑡𝑂𝐷 + 𝑏 ×  𝑛𝑒𝑡𝑂𝐷
2            Equation 3-6 
The polynomial function depends upon associated fitting constants: a, b with errors 
σa, σb, and respectively. The overall estimated uncertainty due to fitting parameters, 
Dfit, is expressed as [74, 132], 
𝜎𝐷𝑓𝑖𝑡(%) =
√(𝑛𝑒𝑡𝑂𝐷 ×𝜎𝑎)2+ (𝑛𝑒𝑡𝑂𝐷 ×𝜎𝑏)
2+(𝑎+2×𝑏×𝑛𝑒𝑡𝑂𝐷)2×(𝜎𝑛𝑒𝑡𝑂𝐷)2
𝐷𝑓𝑖𝑡
× 100   Equation 
3-7 
3.5.3 EBT 3 Film Calibration 
In this thesis, the pre-scanned EBT 3 Gafchromic Films were calibrated under 




photon beam at depth of 1.5 cm and 3.0 cm for 6 and 18 MV photon beam, 
respectively, in a 30 × 30 × 10 cm³ solid water phantom where 10 cm slab thick used 
as the back scattering. The field size was 10 × 10 cm² and SAD = 98.5 cm for 6 MV 
and 97.0 cm for 18 MV and 600 MU/min was set as LINAC dose rate.  
The measurements were performed in a Varian LINAC (Varian Medical System, 
Palo Alto, CA). To obtain the EBT 3 film calibration curve, the 3 × 3 cm2 pre-
scanned EBT 3 film pieces were irradiated to range of doses (10 cGy, 20 cGy, 50 
cGy, 1 Gy, 1.5 Gy, 2 Gy, 5 Gy). The measurements were performed three times and 
then the average reading was used for analysis. Using the above equations, the 
calibration curve was plotted as result of plotting netOD and delivered dose, Figure 
3-9.  
The average calibrated dose uncertainty, calculated using equation 3.7, was 3.32 % 






Figure 3-9 EBT 3 Film Calibration Curve for the red channel using 2nd order 
polynomial fit for (a) 6 MV and (b) 18 MV Photon beam. 
3.6 Brass mesh bolus 
The brass - a metallic alloy which is made of zinc and copper- mesh bolus has been 
studied, in this thesis, as an alternative to tissue-equivalent material.  
In 2008, the Radiation Oncology Department at the University of California, Davis 
(UCD) started using a fine brass mesh bolus (Whiting & Davis, Attleboro Falls, MA) 
when delivering post mastectomy radiation therapy PMRT as an alternative to tissue 
equivalent (TE) bolus [16]. 
The brass mesh bolus is constructed similar to a regular mesh of interlinked brass 
discs, where brass discs are interlocked together to form a mesh, Figure 3-10. It has 
1.5 mm thickness, which is equivalent to 2 mm of tissue. The brass mesh bolus has 





Figure 3-10 Brass mesh bolus. 
 
Similar to a traditional TE-bolus, the brass bolus decreases the radiation build-up 
depth and thereby increases radiation dose delivered to the skin. The most superior 
advantage of brass bolus over tissue equivalent bolus, as previously reported [13, 16, 
135], is ability of brass bolus to conform well to the irregular contours of the chest 
wall with fewer air gaps than TE- bolus material. Furthermore, the local control for 
the surface skin reaction has been shown in previous work that is improved to 
moderate erythema, when brass bolus used [136]. Healy et al. [16] investigated the 
clinical use of brass mesh as an alternative to TE- bolus for patients treated with post 
mastectomy chest wall radiation therapy.  They concluded that, when brass mesh is 
used in chest wall PMRT, the majority of patients (88 %) at the end of treatment 
achieved moderate erythema at cumulative radiation doses of approximately 5 Gy. 
Another benefit of using brass mesh bolus is the reduced impact on the dose at depth 
compared to tissue-equivalent bolus [13, 137]. The resulted data by UCD, during the 
commission of the clinical use of brass mesh, demonstrated that the brass mesh bolus 
did not impact the dose deeper than dmax and that monitor units (MUs) did not change 
significantly with its use. Consequently, the use of brass mesh reduces the 
complexity of accounting for a bolus in simulation and treatment planning, in 




3.6.1 Interaction of MV photon beam with brass material  
The brass is a metallic alloy and its major components are copper with mass 
percentage ranging from about 55 to 95 % and zinc ranging from approximately 5 to 
40 %. 
Since the brass has an intermediate atomic number material (Z = 8.73 g / cm3), the 
dominant interaction between MV photon beams and this medium is the Compton 
Effect, and cross-sections for photoelectric effect, pair production and Rayleigh are 
negligible [138]. The interaction between brass and MV photon beam generates a 
larger quantity of Compton scattered electrons than an equivalent thickness of tissue. 
Therefore, a build-up effect can be produced with a relatively thin layer of brass as 
compared with tissue equivalent bolus. This has the benefit of generating very little 
attenuation of the incoming photon beam.  
3.7   Advanced Markus ionization chamber 
The parallel plate ionization chamber used in this thesis was an advanced Markus 
parallel-plate ionization chamber, Model 34045 (PTW Freiburg, Germany) with 0.02 
cm3 sensitive volume. The physical effective point of measurement for the Markus 
chamber is defined as 0.027 mm, at the inner surface of the proximal collecting plate. 
The plate separation is fixed at 1 mm; the guard ring is 2 mm and the external 
dimensions is 30 mm diameter × 14 mm. The design specifications for the advanced 







Table 3-2 advanced Markus chamber specifications 
Wall 
Material Polymethylmethacrylate 
Density 1.189 g/cm3 
Diameter (w) 9 mm 
Collecting electrode 
Material Graphited PMMA 
Density 1.189 g/cm3 
Separation (s) 1 mm 
Diameter 5 mm 
Window 
Material Polyethylene (CH2) 
Density 0.930 g/cm3 















Figure 3-12 Dimension of advanced Markus chamber type 34045 [140]. 
 
The over-response of the parallel plate ionization chamber is the major limitation of 
this type of chamber, where the charge measured is generated by the secondary 
electrons scattered from the side wall and that by the electron fluence entering from 
the front window [141]. This leads to an over response or increase in the chamber 
readings. The parallel plate chamber over-response can be corrected by applying the 
modified Velkley correction factor. The Velkley correction factor has been modified 
by Rawlinson et al. [142]. It was reported that the over response from the side walls 
is mainly dependent on the ratio of the electrode separation (s) to the diameter of 
wall (w), wall density and wall angle. They further modified the Velkley formula to 
account for the chamber wall diameter, size of the guard ring, separation of electrode 
and the material of chamber.  The Rawlinson formulae which is used in this thesis 
are as follows 
P (d, E) = P’ (d, E, G) – ξ (d, E, G)   Equation 3-8 
ξ (d, E, G) = ξ (0, E, G) × e-4.0d/dmax   Equation 3-9 




where P and P’ are the true and measured percentage depth dose respectively, ξ is 
the over response correction factor, E is the beam energy, d is the depth in the 
phantom, ρ is the mass density of the chamber wall, s/w is the ratio of the electrode 
separation (s) to the diameter of the wall (w). For 6 MV photon beam, dmax is 1.5 cm 
and c(E) = 27 % [143].  
By using Rawlinson formulae, the over response correction factor for the advance 
Markus chamber calculated was 3.45 % at the surface. The calculated over response 
correction factor decreased with the depth, as shown in Table 3-3.  
Table 3-3 Advanced Markus ionization chamber over-response correction factor for 
6 MV photon beam. 








3.8   Attix parallel-plate ionization chamber dosimetry 
The thin-window Attix parallel-plate ionization chamber was selected as the 
reference dosimeter, in the study done in chapter 4 and 5.  The Attix parallel-plate 
ionization chambers are often used to measure surface doses and doses in the build-
up region. It has a 0.125 cm3 collecting volume, and a 4.8 mg / cm2 thick entrance 
window made of conducting Kapton film loaded with graphite. The chamber has a 
diameter of approximately 6 cm, while the entrance window has a diameter of 




3.9   Discussion and Conclusion 
The aim of this chapter is to provide a description of the newly developed n-type 
Skin diode dosimeter and its readout system (TERA). The chapter gives more details 
about the principle of the Skin diode dosimeter and how its readout system works. 
Moreover, the MOSkinTM dosimeter, advanced Markus ionization chamber and 
Gafchromic EBT 3 film were introduced in this chapter. The EBT 3 Film 
preparation, scanning and dose calibration procedure were presented. Additionally, 
this chapter covered some details about the brass mesh bolus which was investigated 














4 Chapter 4 Characterisation of Skin Diode for Skin 
Dosimetry during EBRT 
4.1   Introduction 
Skin dose measurements during radiation therapy is not simple procedure due to the 
substantial dose gradient at the radiation beam entry position. The dose can increase 
by 30 % over the first 1 mm of tissue [145] due to the dose build up effect of 
megavoltage x-ray beams [40, 146].  
In vivo skin dosimetry is a direct method for measuring the dose delivered to the 
patient receiving radiation therapy. It allows the comparison of delivered and 
prescribed doses and thus provides a level of radiation therapy quality assurance that 
supplements port films and computational double checks. 
The investigation of diodes with extremely thin sensitive volumes for skin dosimetry 
has only been reported by Vicoroski et al. [116], who studied the characterisation of 
an n-type diode with 5 µm thick epitaxial layer and p-type silicon diode with 50 µm 
thick epitaxial layer. It was reported that the Skin diode can measure the PDD within 
2 % compared to an ionisation chamber and within 0.5 % agreement of the 
equivalent Monte Carlo simulation (Geant4) curve. Additionally, it was shown the 
Skin diode to have minimal intrinsic angular dependence and a linear dose response 
over a dynamic range from 25 to 500 cGy.  
The goal of this study is to investigate the feasibility of using another design of the 
newly developed n- type Skin diode dosimeter with 7 µm thick epitaxial layer for in 
vivo skin dosimetry for external beam breast treatments by studying its 
characterisation on the surface of a phantom simulating the condition for in vivo skin 




following characterisations were performed: (1) dosimeter calibration, linearity, (2) 
percentage depth dose (PDD), (3) dose rate dependence, and (4) Output Factor (OF). 
Verification and comparisons were performed with previously published studies and 
with other skin dosimeters, including the MOSkinTM, Gafchromic EBT 3 film and the 
Attix ionisation chamber. 
4.2   Materials and Methods 
4.2.1 Calibration of Skin diode and MOSkinTM dosimeters 
The water-equivalent RW3 slab phantom (SP34, PTW-Freiburg, Freiburg, German) 
was used in this study. The RW3 slab phantom has a physical density of 1.045 g 
cm−3 and consists of 30 × 30 cm2 slabs of various thickness ranging from 1 mm to 50 
mm [147].  
The calibration of the dosimeters was performed under the “reference condition” 
Figure 4-1(b-c) where dosimeter is placed at dmax and irradiated with 10 × 10 cm
2 
field size at 98.5 cm Source to Axis Distance (SAD) and 97 cm SAD for 6 MV and 
18 MV photon beams respectively. The characterisation study of the dosimeters was 
carried out under “standard surface setup” Figure 4-1-a where the dosimeter was 
placed at the central axis of the photon beam with face up orientation on the surface 
of a 30 × 30 × 10 cm³ solid water phantom and irradiated with a 6 or 18 MV photon 





Figure 4-1 Schematic of experiment (a) Standard setup for surface measurements. (b) 
Standard reference setup for calibration in a 6 MV (c) Standard reference setup for 
calibration in an 18 MV. 
 
MOSkinTM dosimeters (ten probes) and the newly developed Skin diode were 
calibrated under reference conditions.  
100 MUs of photon beam were delivered for the Attix chamber and Skin diode, 
whereas 40 MUs were delivered each time for the MOSkinTM dosimeters to save their 
lifetime while keeping a reasonable signal. For calibration of both dosimeters, the 
measurements were repeated three times and then the average reading used for 
analysis. 
4.2.2 Dose Linearity 
The linearity of the Skin diode for 6 and 18 MV was checked under standard 
reference conditions as shown in Figure 4-1 (b & c), for dose raging 50 - 500 cGy. 





4.2.3 Dose Rate Dependence 
The dose rate dependence was investigated for both the MOSkinTM and Skin diode 
for 6 and 18 MV photon beam. For all measurements, the dosimeter was placed on 
the surface of the phantom as described above. Each dosimeter was irradiated with 
fixed MUs (40 MU for MOSkinTM and 100 MU for Skin diode), at each of the 
following delivered dose rates: 100 MU/min, 200 MU/min, 300 MU/min, 400 
MU/min, 500 MU/min, and 600 MU/min. All measurements were repeated 3 times 
and the average reading used for analysis. The average reading was normalised to 
300 MU/min. The response variation for each dosimeter was plotted with the given 
dose rates. 
4.2.4 Percentage Depth Dose (PDD) 
Using a field size of 10 × 10 cm2 and SSD of 100 cm, the percentage depth dose 
(PDD) curve for each dosimeter was measured in the 30 × 30 × 10 cm3 RW3 slab 
phantom for a 6 MV photon beam from the surface 0.0 cm up to 20.0 cm depth by 
adding extra RW3 sheets above the phantom, whilst maintaining a constant SSD of 
100 cm.  
The PDD measurements were carried out with three different dosimeters: the Attix 
ionisation chamber, MOSkinTM and the newly developed Skin diode. The results 
represent the average of three continuous readings for each measurement and were 
normalised to the dmax value. 100 MUs were delivered for Attix ionisation chamber 
and Skin diode, with varying MUs delivered for the MOSkinTM dosimeter depending 




The effective point of measurement of the Attix ionisation chamber was taken to be 
at the centre of the front surface of the air cavity, which corresponds to a reference 
depth of 4.8 ×10-3 g / cm2, and result was given with no corrections applied. 
4.2.5 Output Factor (OF) measurement 
The Output factor (OF) is defined as the ratio of the dose per monitor unit at a 
specific field size to the reference field size [148]. In this study, the reference field 
size was 10 ×10 cm2, measured at the isocenter. 
The response of both the MOSkinTM, the Skin diode and Attix ionisation chamber 
dosimeters were measured at 10 cm depth, with 90 cm SSD, for field sizes of 2.5 × 
2.5 cm2, 5 × 5 cm2, 10 × 10 cm2, 15 × 15 cm2 and 20 × 20 cm2 for 6 MV. For an 
Attix ionisation chamber, the smallest field size selected was 5 × 5 cm2 and that is 
due to the chamber’s size. All measurements were repeated three times and the 
average reading was used for analysis. The average reading was normalised to 10 × 
10 cm2. 
4.3   Results and Discussions 
4.3.1 Calibration of Skin diode and MOSkinTM dosimeters  
The sensitivity of the silicon diode is defined as the ionisation charge collected per 
unit of absorbed dose (usually in units of nC / cGy) [149]. The average Skin diode 
sensitivity was 352.74 ± 2.48 pC / cGy. The sensitivity of the Skin diode decreased 
as the accumulated dose increased, due to an increase in the number of radiation 
defects, which causes a reduction in the charge carrier lifetime. This effect was 




The average sensitivity of the ten calibrated MOSkinTM dosimeters in this study was 
measured to be 2.56 ± 0.07 mV/cGy for the 6 MV and 2.43 ± 0.05 for the 18 MV 
photon beam.  
Vicoroski et al. [116] investigated the response of the n-type Skin diode (Epi-5B) 
with 5µm thick epitaxial layer as a function of the dose accumulated from the Co-60 
gamma source and found that the response decreased by a factor of 25 % in the first 
20 kGy of the accumulated dose. For higher doses (more than 60 kGy), the response 
became more stable and the variation was within 2 % that is due to the saturation of 
the diffusion length of the minority carriers [120]. 
4.3.2 Dose Linearity 
Figure 4-2 presents the linearity response of Skin diode for 18 MV for accumulated 
dose ranging from 50 cGy to 500 cGy with 50 cGy increments. A good linearity was 
observed for the response of the Skin diode as a function of dose for 6 and 18 MV 
photon beams. The linearity response of the Skin diode was within ± 1.30 % and ± 
1.01% for 6 MV and 18 MV, respectively. The linear regression analysis showed the 
correlation coefficients (R2) of better than 0.9928 for 18 MV. From the slope of the 
linear fit, the response was 18.35 ± 1.08 pC/cGy, where the conversion factor from 





Figure 4-2 Linearity of Skin diode dosimeter response for 18 MV photon beam. 
4.3.3 Dose Rate Dependence 
No significant dose rate dependence was observed for the MOSkinTM and Skin diode 
for 6 and 18 MV photon beams. The difference was less than 1 %. Figure 4-3.a and 
Figure 4-3.b display the Skin diode and MOSkinTM dosimeter responses for different 
dose rate normalised to 300 MU/min for 6MV and 18 MV photon beams.  
 
Figure 4-3 Skin diode dosimeter responses for different delivered Dose Rate 





Huang et al. [150] found in their study that for 6 MV, there was no difference 
between responses of ion chambers and diodes, i.e. for changes in repetition dose 
rate (MU / min), no correction was needed to correct the diode’s reading to the ion 
chamber’s reading. Vicoroski et al. investigated the dose per pulse dependence 
(DPP) response of the n-type Skin diode dosimeter and found that the Skin diode 
exhibited a variation of less than 5 % within the range between 10-4 and 2.78 ×10-4 
Gy/pulse confirmed by the PDD measurements that presented an agreement within ± 
1 % compared to the parallel plate ion chamber [116]. 
Percentage Depth Dose (PDD) 
Figure 4-4 displays the results of the measured PDD with the MOSkinTM, Skin diode 
and Attix ionisation chamber dosimeters from surface to 20 cm depth in solid water 
phantom normalised to dmax for a 6 MV photon beam with 10 × 10 cm
2 radiation 
field size. PDD differences (%) between the three dosimeters at the surface and 
shallow depths reached to approximately 9.3 % between the Skin diode and Attix 
chamber as shown in Figure 4-5, but beyond the build-up region, PDD differences 
between the dosimeters were less significant. The agreement between the MOSkinTM 
dosimeter and Attix ionisation chamber, was in average 1.9 %, whereas the average 
% differences between Skin diode and Attix ionisation chamber, beyond build-up 





Figure 4-4 Percentage Depth Dose (PDD) measured with MOSkinTM, Skin diode 
dosimeters and Attix ionization chamber of 6MV normalised to dmax, for 10 × 10 cm
2 
field size. 
Vicoroski et al.[116] found in their work that the maximum difference between the 
PDD calculated with Geant4 and measured with the Skin diode was within ± 2 % and 
the difference between Skin diode and the Attix chamber response at surface at 
surface is approximately 2 %. 
The water equivalent measurement depth (WED) of the skin diode was measured by 
another work [116], where the Geant4 radiation transport simulations were used to 
model the PDD. When placed at the phantom surface, the WED of the skin diode 
was estimated to be 0.075 ± 0.005 mm from Geant4 simulations and was confirmed 
using the response of a corrected Attix ionization chamber placed at water equivalent 
depth of 0.075 mm, with the measurement agreement to within 0.3%. 
Figure 4-5 presents the percentage PDD difference between Skin diode dosimeter 




    
Figure 4-5 Percentage PDD difference between Skin diode dosimeter and Attix 
chamber and Skin diode and MOSkinTM dosimeter. 
4.3.4 Output Factor (OF) measurement 
Figure 4-6 shows the response of the MOSkinTM, Skin diode and Attix ionisation 
chamber dosimeters as a function of the field size at depth of 10 cm for a 6 MV 
photon beam within solid water phantom, normalised to 10 × 10 cm2 field size. 
The response trends increased as the field size increased and that is due to the 
increase in the phantom scattering. There was an agreement between the MOSkinTM, 
the Skin diode and Attix chamber measurements as the average % difference 
between the Attix chamber and MOSkinTM was within 1.1 % and it was within 1.3 % 
between the Skin diode and Attix ionisation chamber for the field size larger than or 
equal to 5 × 5 cm2. 
The Skin diode showed an over response at 2.5 × 2.5 cm2 field size, where the % 
difference between the MOSkinTM and the Skin diode reached to more than 40 %. 
This effect is due to perturbation of the radiation field by the larger size of the silicon 
die of the Skin diode in comparison to the MOSkinTM. The relative fraction of the 
beam directly interacting with silicon and surrounding materials of packaging 




and packaging material to take a more dominant role in the response of the silicon 
dosimeter. 
For the largest field size (20 × 20 cm2), the relative response of the Skin diode was 
slightly larger than the MOSkinTM and Attix dosimeters. For the larger field, more 
lower energy scattered photons that will impinge on the diode that can lead to over-
response compared to an ion chamber [82]. 
Additionally, kapton pigtail lateral size and thickness is larger than in case of the 
MOSkinTM dosimeter that contribute to this effect and emphasise importance of 
detector packaging for OF measurements.  
 
Figure 4-6 Percentage Output Factor (OF) response at 10 cm depth measured by 
MOSkinTM, Skin diode dosimeters and Attix chamber at different field sizes 
normalised to 10 × 10 cm2 for 6MV. Error bars for MOSkinTM are small to be 
presented. 
4.4   Conclusion 
In vivo dosimetry is an important component of radiation therapy treatments, as it 




Skin diode dosimeter responses were investigated on a water-equivalent RW3 slab 
phantom surface for different machine dose rates, PDD, and output factor (OF) 
measurement in comparison with MOSkinTM, Gafchromic EBT 3 film and Attix 
parallel plate ionization chamber to determine its stability to be used for in vivo skin 
dosimetry.  
Based on the ICRP recommendation, the Skin diode can be used to measure the skin 
dose since it has WED of 0.07mm.  Moreover, the Skin diode expressed a liner dose 
response over a dynamic range from 50 to 500 cGy for both 6 and 18 MV. 
Comparing to Attix chamber, the Skin diode shows ability to measure PDD within 
2.3 % beyond the build-up region.  The Skin diode has a percentage surface dose of 
25.3 ± 2.0 % and 19.2 ± 2.3 % for 6 MV and 18 MV photon beam, respectively. The 
Skin diode shows promise as a tool for in vivo skin dosimetry, however further 
studies and improvement of the Skin diode stability by improvement of light 















5 Chapter 5 Characterisation of Skin Diode for Skin 
Dosimetry during EBRT: Field Size, Angular 
Dependence and Exit Doses. 
5.1   Introduction  
The importance of measuring the exit and entrance dose is to detect systematic errors 
in the dose delivery during individual patient treatments, which are often related to 
errors in the transfer of information somewhere in the treatment preparation chain. In 
general, entrance dose measurements serve to check the output and performance of 
the treatment source, the accuracy of patient setup, and the calculation of the number 
of monitor units, whereas, exit dose measurements serve, to check the relative dose 
calculation algorithm and to determine the influence of shape, size, and density 
variations of the patient on the dose calculation procedure [151]. Previous studies 
have showed that the measurements of the beam exit dose contributed 50 % more to 
the surface dose than the entrance dose [5]. 
The goal of this chapter is to investigate the feasibility of using the newly developed 
n- type Skin diode for in vivo skin dosimetry by studying its characterisation on 
surface of a phantom simulating the condition for in vivo skin dosimetry (where non-
CPE condition exists) for megavoltage photon beams. The following 
characterisations were performed: (1) field size and angular dependence; (2) surface 
dose measurement; and (3) exit dose measurement. Verification and comparisons 
were performed with previously published studies and with other skin dosimeters, 




5.2   Materials and Methods 
5.2.1 Field size and Angular Dependences  
In the current study, the Attix chamber, MOSkinTM, Skin diode and EBT 3 film 
dosimeters were carried out under the standard surface setup as mentioned in section 
4.2.1, where the CPE does not exist, since the MOSkinTM and the newly developed 
Skin diode will be used for in vivo skin dose measurement. The dosimeters were 
irradiated under different beam incidence angles from 0 to 60° measured from the 
normal to the phantom surface in 15° increments.  For each gantry rotation, the 
response of each dosimeter was investigated by irradiating them to different field 
sizes (2.5 × 2.5, 5.0 × 5.0, 10.0 × 10.0, 15.0 × 15.0 and 20.0 × 20.0 cm²) for 6 MV 
and 18 MV photon beams. 
To keep the MOSkinTM signal (i.e., the change of the threshold voltage) at a moderate 
level different MUs were delivered depending on the selected field sizes. The 
readings were corrected to a fixed irradiation of 100 MU and were then normalised 
to the dmax value. To optimise the 
film response, a different number of MUs was given, depending on field sizes used, 
to keep a delivered dose of approximately 100 cGy for all the measurements. The 
estimation of the number of MUs was based on the field size, with the field size 
increasing the number of MUs delivered was decreased proportionally based on 
known LINAC beam model keeping approximately the skin dose about 100 Gy. All 





5.2.2 Exit Dose Measurement 
A simple geometry was followed to measure the beam exit doses in our study. They 
were measured for the EBT 3 film, Attix ionisation chamber, MOSkinTM and Skin 
diode. The pre-scanned EBT 3 film with size of 3 × 3 cm2, was placed on central axis 
of the beam on the surface of the 30 × 30 × 10 cm3 slab water phantom relative to the 
incident beam (0° gantry angle). The SSD was set to 100 cm on the surface of the 
phantom and 10 × 10 cm2 was set as the radiation field size. The gantry was then 
rotated to 180° to measure the beam exit dose measurement. 500 MU was delivered 
for each of the field sizes (2.5 × 2.5, 5 × 5, 10 × 10, 15 × 15, 20 × 20) cm2. For each 
field size, the measurement was repeated three times. The same steps were repeated 
for Skin diode and Attix chamber, with 100 MU delivered for the Skin diode and 80 
MU delivered for the MOSkinTM. 
5.3   Results and Discussions 
5.3.1 Field size and angular dependence  
The field size dependence of the surface dose measured with the Skin diode and 
MOSkinTM dosimeters, as well as EBT 3 film and Attix ionization chamber, are 
shown in Figure 5-1 and Figure 5-2 for 6 MV and 18 MV photon beams, 
respectively. All readings were normalised to 10 × 10 cm² field size. As expected, 
the four dosimeters showed an upward trend as field size increased, due to the 
increase in photon head scatter and radiation contamination. Their readings were less 
dependent upon the phantom scatter and heavily dependent on the head scatter [150, 
152, 153].  The head scatter was mainly due to the scattered radiation from the 








Figure 5-1 Field size response of the surface dose measured with MOSkinTM, Skin 
diode, Gafchromic EBT 3 film, and Attix ionization chamber normalised to response 








Figure 5-2 Field size response of the surface dose measured with MOSkinTM, Skin 
diode, Gafchromic EBT 3 film, and Attix ionization chamber normalised to response 






For a normal incident beam, Figure 5-1. (a), there was an agreement between the 
Skin diode and MOSkinTM dosimeter relative responses for all field sizes, it was 
within 3.7 % for 6 MV photon beams, except at the smallest field size of 2.5 × 2.5 
cm2, the % difference was 5.9 %. This effect was due to the perturbation of the 
radiation field by the larger size of the silicon die of the diode. The relative fraction 
of the beam directly interacting with silicon surrounding sensitive volume (SV) 
increased, as the field size decreased. This causes the electrons scattered from 
surrounding silicon a more dominant role in the response of the dosimeter. The same 
effect of the surrounding SV silicon was responsible for 3.7 % difference between 
the Skin diode and MOSkinTM dosimeter responses the bigger field size (20 × 20 
cm2) but mostly due to side scattering effect. 
Our results matched with a study by Lee et al. [154], who observed that there are 
small differences of up to ± 3 % between the diode and ion chamber measurements 
for both the 6 MV and 18 MV for field sizes from 5 × 5 cm2 to 40 × 40 cm2. In this 
study, the maximum percentage difference between the Skin diode and Attix 
ionisation chamber was 3.93 % for 6 MV and 3.5 % for 18 MV. For the 10 ×10 cm2 
field size, the percentage dose deposited on the surface of the phantom is expected to 
be 10 % – 20 % of the maximum dose (dmax) [129], which depends on the WED of 
the dosimeter and the LINAC used. In the current work, the mean surface dose 
relative to dmax was 18.5 ± 1.7 %, and 16.2 ± 0.1 % for the MOSkin
TM dosimeter and 
Attix chamber respectively under the normal beam incidence. These results were 
match with other studies with MOSkinTM dosimeter [5, 94]. Kwan et al. [94] 
measured the mean percentage dose deposited on the surface of the six MOSkinTM 
dosimeters for 10 × 10 cm2 field to be 18.3 ± 0.7 %, compared to an Attix chamber 




as 18.95 ± 0.03 % for an Attix chamber and 19.49 ± 1.70 % for MOSkinTM in a water 
equivalent phantom for 6 MV photons.  
The Skin diode measured a mean percentage surface dose of 25.3 ± 2.0 %. The 
response of the MOSkinTM dosimeter was quite similar to the response of the Attix 
ionisation chamber, while the mean surface dose measured by the Skin diode was 
much greater. The percentage dose at the surface measured by the  Skin diode 
matched with the response of the epoxy bubble packaged MOSFET dosimeter 25.5 ± 
1.3 % corresponding to effective WED of the packaged commercial MOSFET of 1.8 
mm as demonstrated by Akbas at el. [131], who investigated the percentage dose at 
the surface and build up region by MOSFET dosimeter, Markus chamber and EBT 3 
film. Since EBT 3 film has a WED of 0.153 mm while placed on the surface of the 
phantom, they used the extrapolation calculation to acquire the dose at 0.07 mm 
WED. They obtained that the percentage surface dose was 18.8 % for EBT 3 with 10 
× 10 cm2 field size and 100 cm SSD at 0.07 mm depth. Devic et al. [71] measured 
the skin dose with radiochromic EBT film at 0.07 and 0.153 mm depths for 6 MV 
(Varian Clinac 2100 C/D linear accelerator) photons. It was reported that the surface 
doses were 17.0 % at 0.07 mm, and 19.9 % at 0.153 mm depth for 10 × 10 cm2 field 
sizes. Our study showed coherency with these publications for a 6 MV Photon beam. 
For 18 MV photon beam, the percentage surface dose measured for normally 
incident photon beam was 19.2 ± 2.3 % and 14.9 ± 0.3 % with the Skin diode 
dosimeter and the Attix ionization chamber, respectively. 
An important source of discrepancy of using dosimeter is their response for angled 
fields. Treatment fields such as tangential fields for breast radiation are subjected to 
incident beam not perpendicular with the surface of the dosimeter. In order to 




the Gantry position were evaluated at various angles from 0° to 60° in 15° 
increments. The dosimeter readings were normalised to the reading obtained at 0° 
gantry angle for a 10 × 10 cm2 field size, and an SSD equal to a 100 cm. 
Figure 5-3 shows the response comparison between MOSkinTM dosimeter, Skin 
diode, Attix ionisation chamber and EBT 3 Film with different beam incident angles 
for 6 MV and 10 × 10 cm2 field size. The measured surface dose increased, as the 
beam incident angle increased. The result is expected as the effective depth of 
measurements is increasing by 1 / cos (ɵ). Increasing the beam incident angle ɵ leads 
to larger number of secondary electrons being ejected along the oblique path of the 
beam [89, 129, 155]. Additionally, this increase is due to the intrinsic dosimeter 
design, which results in an asymmetric structure along polar axis of dosimeter and 
leads to photon traverse a greater path length through dosimeter sensitive volume. 
The Skin diode dosimeter showed lower angular dependence with beam incident 
angles in the range between 0 and 60 degrees comparable with the other dosimeter 
responses, as presented in Figure 5-3 and Figure 5-4. They show that the Skin diode 
has a minimal angular dependence comparable with the Attix chamber response, 
where the Attix chamber response shows a larger response up to + 20 % at 60° as 
confirmed by other studies [123]. With increasing of an incidence angle, the skin 
dose is increasing. The Attix chamber is considered as a gold standard and 
MOSkinTM is closer to Attix but not the same because slightly different WED of 
measurement. Skin diode dosimeter under-responses in comparison with Attix and 
MOSkinTM because WED of measurements larger and size of the chip is larger than 




The MOSkinTM dosimeter agreed with the Attix chamber at lower gantry angles (˂ 
45°), where the average % difference was 2.3 %, but at higher gantry angle 60°, the 
% difference was 9.4 % with Attix chamber and 7.6 % with EBT 3 Film. 
Some previous studied showed that the commercially available surface diodes are 
found to have as great as 25 % change in sensitivity with the angle of incidence of 
radiation. This becomes a problem if the measured surface has an irregular shape, 
which will cause the front surface of the diode to be oblique to the incident direction 
of the radiation. A similar problem occurs if there is significant scattered dose from 
adjacent surfaces [80].This is why commercial diodes are not suitable for skin 







Figure 5-3 Surface angular dependence responses measured with Skin diode, 
MOSkinTM dosimeters and Attix chamber as the function of beam incident angle and 
different field sizes for 6 MV photon beam. 
 
 
Figure 5-4 Surface angular dependence responses measured with Skin diode, Attix 
chamber and MOSkinTM dosimeters as the function of beam incident angle and 




5.3.2 Exit Dose Measurements 
The exit dose measurements for the four dosimeters are presented in Figure 5-5. 
There was an agreement between Skin diode and Attix ionization chamber to within 
± 2.4 %. The maximum % difference (approximately 6.2 %) was at the highest field 
size of 20 × 20 cm2. This is may be due to increasing of lower energy photon 
backscatter contribution and design of the Skin diode as described above. 
The exit dose measurements for the MOSkinTM with face-out and face-in orientation 
were performed. When face-out, there is a great reduction in backscatter dose to the 
sensitive volume. The response of the face-out MOSkinTM orientation was 55.2 ± 0.6 
cGy, whereas the response with face-in orientation was 65.6 ± 0.9 cGy and this is 
expected results, due to attenuation in the substrate region of the MOSkinTM 
dosimeter. This is because of the difference in the WED (asymmetric geometry) of 
the MOSkinTM. For Face-down orientation, the WED is approximately 0.9 mm as a 
result of a 0.4 mm thick silicon substrate faced to the X-ray beam in contrast to WED 
0.07 mm in face on orientation determined by thickness of polyamide film only. 
Thus, it is a vital to use correct orientation of the MOSkinTM dosimeter when it is 
used for skin dose measurement or entrance and exit doses. The current work was in 






Figure 5-5 Beam exit dose measured by MOSkinTM, Skin diode dosimeters, EBT 3 
Film and Attix chamber. a) exit dose in cGy. b) exit dose in % 
5.4   Conclusion 
In vivo dosimetry is an important component of radiation therapy treatments, as it 
ensures the accuracy of the dose delivered to the treatment volume. The newly 
developed n-type skin epitaxial diode responses were investigated on a water-
equivalent RW3 slab phantom surface for different field sizes, surface dose, oblique 
beams and exit dose measurement in comparison with MOSkinTM, EBT 3 
Gafchromic film and Attix parallel plate ionisation chamber to determine its stability 
to be used for in vivo skin dosimetry. 
The Skin diode showed an adequate response to radiation from different field sizes. 
There was an agreement between the Skin diode and MOSkinTM dosimeter in OF 
measurements for all field sizes beyond 2.5 × 2.5 cm2, within 3.7 % for 6 MV photon 
beams. The Skin diode measured percentage surface dose of 25.3 ± 2.0 % and 19.2 ± 
2.3 % for 6 MV and 18 MV photon beams with 10 × 10 cm2 field size, respectively. 






6 Chapter 6 Dosimetric Effects of Brass Mesh Bolus on Skin 
Dose and Dose at Depth for Postmastectomy Chest Wall 
Irradiation 
6.1   Introduction 
The most widely used treatment modality for postmastectomy radiation therapy 
patients is megavoltage photon external-beam radiation therapy, particularly utilising 
the tangential beam arrangement. Megavoltage photons are usually used for their 
depth of penetration properties whilst providing skin sparing effects. For 6-MV 
photons, the depth of maximum dose (dmax) is 1.5 cm, with the surface dose 
substantially lower. For opposed tangential fields, the skin receives approximately 80 
% of dose prescription due to this sparing effect [16]. The skin sparing effect of the 
MV beam is not desired in the case of chest wall, where the target extends to the 
skin, based on the definition of the Radiation Therapy Oncology Group (RTOG) for 
the  chest-wall target volume [156].  
Tissue-equivalent material bolus is commonly used during post-mastectomy 
radiation therapy to provide an adequate dose build-up prior to the skin and 
superficial chest wall [11, 12]. Commercially available tissue-substitute materials are 
Superflab and Vaseline based bolus. Previous studies have shown a few limitations 
of using these types of bolus. One of these is the lack of conformity to the chest wall 
due to its thickness, rigidity and inflexibility, which will reduce the efficiency of the 
build-up material. It has been shown that the surface dose may decrease by as much 




gap between  skin of a patient and the bolus may lead to harmful hot spot doses or 
underdosage [15].  
A second issue with tissue-equivalent bolus has been identified by Ordonez-Sanz et 
al. [13]. They demonstrated the difficulty in maintaining a uniform thickness across 
the bolus surface when Vaseline bolus is used for breast radiation therapy. The bolus 
was shown to be very thin at the most anterior part of the breast, providing less build-
up material, leading to a lower dose at the skin. 
Another drawback of tissue-equivalent bolus is the requirement of two treatment 
plans (one for the bolus and another plan for no bolus) due to the attenuation 
differences in the absence and presence of the bolus. The need for two treatment 
plans increases the workload for centres, which use the TE bolus.  
The brass bolus is an alternative to tissue-equivalent bolus that has been adopted by 
UCD in 2008. The brass mesh bolus is constructed similar to a regular mesh of 
interlinked brass discs, where brass discs are interlocked together to form a mesh, as 
shown in Figure 3-12. It has 1.5 mm thickness, which is equivalent to 2 mm of 
tissue. The brass has density of 8.73 g/cm3 and  a cross section of 45 × 45 cm2 cross 
sectional as dimension [133, 134].  
Like a traditional TE-bolus, the brass bolus decreases the radiation build-up depth 
and thereby increases radiation dose delivered to the skin. The most superior 
advantage of brass bolus over tissue equivalent bolus, as previously reported [13, 16, 
135], is the ability of brass bolus to conform to the irregular contours of the chest 
wall with fewer gaps, compared to TE- bolus material. Furthermore, the local control 
for the surface skin reaction has been shown in previous work to be improved to 
moderate erythema, when brass bolus used [136] . Healy et al. [16] investigated the 




postmastectomy chest wall radiation therapy.  They concluded that when the brass 
mesh is used in chest wall PMRT, the majority of patients (88 %) at the end of 
treatment achieved moderate erythema at cumulative radiation doses of 
approximately 5 Gy for the skin. Another benefit of using brass mesh bolus is the 
reduced impact on the dose at depth compared to tissue-equivalent bolus [13, 137]. 
The results from a study performed by UCD, during the commission of the clinical 
use of brass mesh, demonstrated that the brass mesh bolus did not influence the dose 
below dmax and that monitor units (MUs) did not change significantly. Consequently, 
the use of brass mesh reduces the complexity of accounting for a bolus in simulation 
and treatment planning, and as such only one treatment plan is required [16]. 
The goal of this research is to investigate the feasibility of using the brass mesh bolus 
as an alternative to tissue- equivalent (TE) bolus for post mastectomy chest wall 
cancer. Dosimetric characterisations of a 2-mm fine brass mesh bolus was performed 
in terms of the effect of brass bolus on dose at the surface (beam entry and exit), as 
well as beam profiles and percentage depth doses. What is unique in this study is that 
the measurements were performed using MOSkinTM dosimeter, which has compact 
size and fine resolution, thus achieving more accurate skin measurements under the 
fine structure of the brass spaces and discs. Different configurations were compared 
in this work are: Face-up brass bolus, Face-down brass bolus, double brass bolus and 
TE-Superflab bolus, as shown in Figure 6-1. The construction of the mesh brass 
bolus is different from both sides. More details about brass mesh bolus was 





Figure 6-1 Bolus materials used in this study: (a) Face-up brass mesh bolus, (b) Face-
down brass mesh bolus, (c) Superflab TE bolus.  
6.2   Materials and Methods 
6.2.1 Attenuation effect of brass mesh bolus 
The effect of the attenuation of the brass mesh bolus on the dose deposition was 
evaluated using an advanced Markus parallel-plate ionization chamber 0.02 cm3, 
Model 34045 (PTW Freiburg, Germany). The physical effective point of 
measurement for the Markus chamber is defined as 0.03 mm, at the inner surface of 
the proximal collecting plate. The plate separation is fixed at 1 mm; the guard ring 
width is 2 mm and the external dimensions are 30 mm diameter × 14 mm. The 
Markus chamber was placed on the central axis of a 10 × 10 cm2 field size 6 MV 
photon beam, 100 SSD cm at a depth of 10 cm in a 30 × 30 × 10 cm3 solid water 
phantom. The PTW Unidos electrometer was used to operate the Markus chamber at 
a potential of + 300 V. The attenuation factor was determined as the ratio of 




attenuation factor for one-layer and double layer of brass bolus as well as the TE- 
Superflab bolus were determined. The over response correction factors for the 
advanced Markus chamber was calculated using the modified Velkley correction 
formula [142, 143].  
6.2.2 Percentage depth dose (PDD) measurements 
The central axis (CAX) PDDs were measured using 3 × 3 cm2 Gafchromic EBT 3 
film pieces, which were aligned parallel to the couch. Solid water blocks with an area 
of 30 × 30 cm2 were used to provide the proper scattering conditions, with a slab 10 
cm thick for the back-scattering material and multiple slabs to obtain the depth dose 
profile from 0 to 10 cm depth. The films were irradiated with 300 MU by 10 × 10 
cm2 field at 100 cm SSD by a 6 MV photon beam on a Varian Clinac 21EX Linear 
accelerator (Varian Medical Systems, Palo Alto, CA). These measurements were 
taken with one-layer of a Face-up brass mesh bolus placed on top of the phantom, 
then repeated with the double layer of brass mesh bolus. The results were compared 
with measurements obtained with the Markus ionization chamber under the same 
conditions in solid water for the following cases: one-layer Face-up of brass, Face-
down brass, double brass and 0.5 cm and 1.0 cm TE- Superflab bolus. 
6.2.3 Exit dose measurements 
The exit doses were measured on the central axis of the 6 MV photon beam using a 
MOSkinTM dosimeter (Face-up orientation). The dosimeter was placed on the surface 
of the 30 × 30 cm2 of solid water, with a slab 10 cm thick for the attenuating 
medium. The gantry of the LINAC was rotated to 1800 and irradiation was carried 
out with a 10 × 10 cm2 radiation field and 100 cm SSD. These measurements were 




and then Face-down of brass mesh bolus placed on top of the phantom. The same 
steps were performed with the advanced Markus ionization chamber to measure the 
exit dose for the cases of one-layer Face-up, Face-down, double layer of brass mesh 
bolus and also for the cases of a 0.5 cm and 1.0 cm thick layer of tissue-equivalent 
Superflab bolus.  
6.2.4 Surface beam profile measured on curved phantom. 
To simulate the effect of the breast curvature on the surface doses underneath the 
brass mesh, surface dose profiles were measured with a 6 MV tangential beam (900 
tangent field) measured with 6 × 20 cm2 EBT 3 film strips, which were placed above 
the curved phantom (20 cm length and 7.5 cm radius). The film strips were taped 
carefully on the curved phantom make sure that an air gap between the film and the 
phantom do not exist. The curved phantom was placed above a 10 cm thick solid 
water phantom on the couch of the LINAC, as shown in Figure 6-2. The 
measurements were performed for 10 × 10 cm2 and 100 cm SSD and 100 MU was 
delivered. The measurements were repeated with Face-up, Face-down and double 







Figure 6-2 Curved phantom with brass mesh bolus. 
6.3   Results and Discussions 
6.3.1 Attenuation effect of brass mesh bolus 
For this research, the polarity effect of the Markus chamber was evaluated. The 
percentage difference between the positive and negative 300 bias voltage readings 




The brass mesh bolus attenuated the 6 MV photon beam by a factor of 0.994 and 
0.986 for one layer, and two layers, respectively, as shown in Table 6-1. The 
attenuation factor of the brass bolus when flipped in the Face down configuration and 
placed over the phantom attenuated the 6 MV photon beam by 0.57 %, that is due to 
the construction of the brass bolus, as can be seen in figure 6.1 (a and b), the brass 
has more hollow structures from Face down than Face up orientation. The TE-
Superflab bolus attenuated the beam more than the brass bolus. The presented results 
show the benefit of the comparatively thin layer of high Z brass material that 
produces a larger quantity of Compton scattered electrons than an equivalent 
thickness of tissue and generating very little attenuation of the incident photon beam.  
Table 6-1 The attenuation effect of the brass and TE- Superflab bolus on the photon 
beam measured with the Markus ionization chamber. 
Face-up brass Face-down brass Double brass 0.5cm TE bolus 1.0 cm TE bolus 
0.62 % 0.57 % 1.40 % 1.91% 3.59 % 
 
Richmond et al. [157] evaluated the attenuation factors for the  Flattening Filter (FF) 
and  Flattening Filter Free (FFF) 6 MV photon beams, and found no difference 
between them, obtaining 0.993 as a factor for both FF and FFF beams with one brass 
layer and 0.987 and 0.986 with two brass layers bolus , respectively. For 15 MV 
photon beam, the attenuation factors were 0.995 and 0.989 with one and two layers 
of brass, respectively [157]. 
It can be seen that the values of attenuation factors are small and can be easily 
incorporated in patient treatment monitor unit calculations to account for the 




6.3.2 Percentage depth dose (PDD) measurements. 
To correct for the over response of the advanced Markus chamber, Rawlinson’s 
formula was used to calculate the correction factor, which was calculated to be 3.6 % 
at the surface and then decreased with depth. 
The comparisons of the PDD curves of 6 MV photon beam, normalised to a depth of 
dmax, with a 10 × 10 cm
2, 100 cm SSD, measured with advanced Markus ionization 
chamber in a solid water phantom for the cases of one-layer Face-up brass mesh 
bolus, double layer brass mesh bolus (Face-up orientation) and no brass bolus are 






Figure 6-3 PDD curves for 6 MV beam measured with an advanced Markus 
ionization chamber for the cases of no brass bolus, Face-up brass bolus, Face-down 
brass bolus, double brass bolus, 0.5 cm and 1.0 cm TE- Superflab bolus. The second 
sub-Figure is PDD curves in build-up region.  
 
Figure 6-3 shows that by placing brass or TE- Superflab bolus in the irradiating field, 
the PDD curves altered in the build-up region in comparison to the results obtained 
for the open field irradiation. Both brass and TE- Superflab bolus shifted the PDD to 




place within the brass and tissue equivalent bolus materials. The effect of the brass 
bolus on the PDD curves was less than the TE- Superflab bolus because brass bolus 
has a smaller tissue-equivalent thickness (2 mm tissue-equivalent thickness 
according to the manufacturer) than TE- Superflab bolus and additionally, the high 
Z-brass material is hardened the beam. 
Table 6-2 shows the surface dose as a percentage of the dose at dmax with the Markus 
ionization chamber, EBT 3 Film and MOSkinTM for different bolus arrangements at 0 
mm and 100 mm depth. The brass bolus increased the surface PDD from 22.8 ± 1.2 
% to 61.2 ± 1.1 %, 56.7 ± 1.0 %, and 75.2 ± 1.2 % with one-layer Face-up, Face-
down and the double layer of the brass bolus, respectively, as measured with the 
Gafchromic EBT 3 film. In contrast, the TE- bolus increased the surface dose to 89.6 
± 1.1 % for 0.5 cm thickness and 102.2 ± 1.3 % for 1.0 cm thickness. The surface 
corrected PDD measured under the bolus by Markus ionization chamber enhanced 
the surface PDD from 16.5 % to 54.4 %, 53.1 % 71.9 %, 89.1 % and 101.1 % with 
Face-up brass, Face-down brass, double brass bolus, 0.5 cm and 1.0 cm TE- 
Superflab bolus, respectively. The agreement between MOSkinTM measurements and 
Markus chamber measurements were within 3 %. The surface PDD measured under 
the brass bolus with the MOSkinTM dosimeter increased from 19.2 ± 1.0 % to 57.2 ± 
1.7 % and 51.4 ± 1.3 % for Face-up and Face-down brass bolus, respectively. The 
EBT 3 film showed higher responses than the other dosimeters. This disagreement 
can be explained due to the differences in WED for used dosimeters [131, 143]. The 
WED of Gafchromic EBT 3 film was determined based on the physical depth and 
density from the surface to the centre of the active layer. The Gafchromic EBT 3 film 
has 0.153 mm WED [71], whereas MOSkinTM dosimeter has a WED of 0.070 mm 




Table 6-2 The surface PDD measured with Markus ionization chamber, EBT 3 Film 
and MOSkinTM under brass and TE- Superflab bolus at 0 and 100 mm depth. 
0 mm (surface) 
 Markus * EBT 3 Film MOSkinTM 
no bolus 16.5 22.8 ± 1.2 19.2 ± 1.0 
Face-up brass 54.4 61.2 ± 1.1 57.2 ± 1.7 
Face-down brass 53.1 56.7 ± 1.0 51.4 ± 1.3 
double brass 71.9 75.2 ± 1.2  
0.5cm TE-bolus 89.1 89.6 ± 1.1  
1.0cm TE-bolus 101.1 102.2 ± 1.3  
100 mm depth 
 Markus * EBT 3 Film  
no bolus 65.9 68.7 ± 1.1  
Face-up brass 65.6 68.5 ± 1.2  
Face-down brass 65.7 68.5 ± 1.0  
double brass 65.4 69.3 ± 1.2  
0.5cm TE-bolus 64.6 65.7± 1.3  
1.0cm TE-bolus 65.1 70.4 ± 1.1  
              *SD = 0 % for Markus ionization chamber. 
Manger et al.[137] measured the surface PDD curves for 6 MV with an Advanced 
Markus ionization chamber and obtained 25 % for no bolus, 63 % for one layer of 
brass bolus and 90% for 0.5 cm of Superflab bolus. Whereas, the measured PDD at 
10 cm depth (100 cm SSD) was 68.2 % for no bolus, 68.0 % for brass mesh bolus, 
and 66.2 % for tissue-equivalent bolus. Richmond et al. [157] studied the surface 
dose for the open 10 × 10 cm2, 6 MV beam and measured 14 % of the dose at dmax 
and one layer of brass bolus enhanced this to 44 % where two layers increased the 
skin dose to 62 % of the dose maximum value. 
Gong et al. [158] found the 6 MV surface dose to be 15 % lower with one layer of 
mesh than that with the 0.5 cm of tissue-equivalent bolus. These results indicated a 




where their result was 37 %. For two layers of the brass bolus, the surface dose was 
17 % less than that with 0.5 cm TE-bolus. The was an agreement between our results 
in this paper and the previous literature.  
The influence of the bolus decreases with depth. The percentage difference between 
the doses measured with and without bolus at 100 mm depth, measured with the 
advanced Markus ionization chamber were evaluated. The results are presented in 
Figure 6-4.  
 
Figure 6-4  Percentage difference in PDD measured with Markus ionization chamber 
at depth 10 cm with and without brass bolus.   
 
The doses measured by the Markus ionization chamber at a depth 100 mm were 
similar for one-layer brass mesh bolus versus no brass bolus. The percent difference 
was 0.3 % with one-layer Face-up and Face-down brass bolus versus without bolus, 
whereas the doses decreased by approximately less than 0.6 % for the double layer of 
the brass bolus. On the other hand, the percentage difference was 0.9 % and 1.3 % 
with 0.5 cm and 1 cm TE- Superflab bolus versus without bolus, respectively. These 
results presented a good agreement with previous works.  
Richmond et al. [157] found that for 90 cm SSD 6 MV, the changes in the 
percentage depth-dose curves beyond dmax to 25 cm depth, was ˃ 0.3 % between 























phantom surface. Another previously published data reported that the changes in 
PDD were ˂ 0.7 % when one layer of brass mesh bolus was used with 6 or 15 MV 
photon beams [13, 159]. Ordonez-Sanz et al. [13] results demonstrated that the 5-mm 
Superflab bolus modifies the doses at depth by up to 2.8 %, therefore the bolus 
would needs to be accounted for in the TPS.  
Attenuation of the photon beam increases with additional layers of brass mesh. These 
results indicated that low energy electrons produced by the brass mesh contributed to 
increased dose up to 15 mm. Beyond 15 mm depth these electrons no longer 
contributed to absorbed dose and attenuation of the beam by the brass mesh becomes 
negligible. Thus, the high-density mesh has little effect on the spectrum of the 
irradiating photon beam, as demonstrated by the negligible change in measured 
depth-dose characteristics. 
Recently published data by Ordonez-Sanz et al. [13] determined that PDD at 1mm 
depth as measured by TLD was 50 % for 6 MV open-field irradiation, which 
enhanced to 70 % with the use of the brass mesh bolus. These measurements showed 
that the dose at 1 mm depth increased from 45 % to 66 % and 79 % for one and 
double layer of brass, respectively. For 0.5 cm TE-Superflab bolus, the dose 
increased to 93 % at 10 cm depth. The results of this study showed that the double 
layer of brass enhanced the PDD to 93.1 % at depth of 3 mm.  
S. Gibb et al. [160] made measurements at 100 cm SSD in a phantom perpendicular 
to the beam central axis using double layers of brass mesh. It was reported that the 
PDD at 4 mm depth increases from 77 % with no bolus to 94 % using 3 layers of 
brass mesh.  
Our measurements displayed that more than two layers of brass mesh bolus required 




the study performed by Richmond et al. [157]. Other publications have 
recommended that more than two brass mesh sheets should be added to attain the 
clinical requirements. Irwin et al. [161] indicated that four layers of brass mesh 
would be required to equate to the bolus effect of 0.5 cm of Superflab, and Gong et 
al. [158] suggested three layers. Fessenden at el. [133] stated in his work that Four 
layers of a brass fabric, each having an average areal density of 0.25 g/cm2, are used 
as the bolus for 6 MV, and three layers are used for 4 MV. 
6.3.3 Exit dose measurements. 
The attenuation of the fiber LINAC couch was measured previously in the 
department during their clinical commissioning and it was found that fiber couch 
attenuated only 1 % of the photon beam. The resulted exit dose measurements are 
presented in Table 6-3. With one layer of brass bolus covering the surface of the 
solid water phantom, the measured exit dose increased to above 78 % for both Face-
up and Face-down brass bolus configuration as measured with a Markus ionization 
chamber. The exit dose increased to approximately 86 % for two layers of brass 
mesh covered the exit surface. The dose enhancement with TE- Superflab bolus were 
less than the brass. The TE- Superflab bolus increased the dose to only 63 %. The 
measurements performed with a MOSkinTM dosimeter showed the exit doses were 
73.1 % and 72.3 % for Face-up brass and for Face-down brass bolus, respectively.   
Richmond et al. [157] found that the exit dose for one layer of brass bolus in a  6 
FFF MV field  was increased from 52.1 % to 74.4 % , which increased to 80.1 % 
with two brass layers. They also concluded that the high Z brass bolus generates a 




measured dose near the exit surface of the phantom. The dose increases with the 
brass material much greater than that seen with full backscatter in water. 
Table 6-3 Exit dose measured under different cases of bolus with Markus ionization 
chamber and MOSkinTM dosimeter. 
 Markus * MOSkinTM 
no bolus 53.8 47.9 ± 0.5 
Face-up brass 78.7 73.1 ± 0.4 
Face-down brass 79.3 72.3 ± 1.9 
double brass 85.9  
0.5cm TE-bolus 63.1  
1.0cm TE-bolus 63.2  
* SD = 0 % for Markus ionization chamber. 
The exit dose is the significant component of the dose near the surface in the opposed 
tangential field treatment. Some authors evaluated the exit and build-down dose 
using film and a cylindrical water phantom [133].  
Neil Richmond [162] calculated the build down and central axis exit dose for 15 MV 
photon beam using a source to surface distance of 90 cm with 10 × 10 cm2 field size 
beam exiting thought the bolused surface of the phantom. The calculated build-down 
dose at the exit surface of the phantom with one layer of mesh present for the 15 MV 
beam models is shown in Figure 6-5. As can be seen from this Figure, Monte Carlo 
algorithms, which are more accurate TPS algorithms in surface dose calculation, 
showed an increased exit dose, which is justified due to the back scattered photons 
from the brass. From this Figure, the exit dose was calculated as 56 %, 55 % and 49 





Figure 6-5 Comparison of 15 MV photon build-down dose curves generated by the 
three planning system algorithms for 10 × 10 cm2 collimator setting, 90 cm SSD with 
one layer of brass mesh bolus at the beam phantom exit surface [162] 
6.3.4 Surface beam profile measured on curved phantom.  
The measured PDD on the surface of the curved phantom using a 6 × 20 cm2 
Gafchromic EBT 3 film strip using no bolus, Face-up, Face-down, double brass 
bolus, 0.5 cm and 1.0 cm TE- Superflab bolus with 6 MV tangential field beam (900) 







Figure 6-6 Surface dose profiles from medial (negative) to lateral (positive), using 6 
MV lateral tangential beam (900) measured with 6 × 20 cm2 Gafchromic EBT 3 film. 
0° on the x-axis represents the anterior surface of the phantom with ± 90° the 
posterior edges of the tangential field. 
 
The surface dose profiles for the Face-up, Face-down and double brass bolus cases 
resembled the profile for the no bolus, whereas, the TE-bolus surface dose profiles 
presented different patterns, similar to the photon beam profile. For a tangential field, 
the tissue-equivalent bolus produced a flatter surface-dose profile with a higher 
average surface dose over the medial to lateral extent of the breast. 
As compared with the unbolused irradiation field, the surface dose at zero degrees 
was enhanced by the brass mesh and TE-Superflab bolus. This was simply due to the 
dose build-up and backscattering effects created by the two different bolus materials.  
The brass mesh was clearly enhancing the surface dose from that seen with no bolus 
but not by as great an extent as 0.5 cm and 1.0 cm of Superflab. Although two layers 
of brass bolus were placed above the phantom, the surface dose was less than the 




dose for the cases of the brass bolus increased towards the apex of the phantom. This 
is a result of backscatter dose enhancement on beam exit with the brass mesh.  
In the curved phantom measurements, the skin doses are affected considerably by the 
obliquity, the more glancing the beam with respect to the surface, the greater the 
dose.  
Jackson at el. [163] has shown that the skin sparing may be reduced significantly by 
obliquity. Jackson has a theory called electron range curve theory, which can be used 
to forecast the effects of obliquity, especially for a simple unbolused surface with 
only an entering beam. However, since the opposed tangential field treatment with 
fractional blousing involves other factors, namely the bolus, the inverse square law, 
exit dose, and interface effects, skin dose is best determined by direct measurement 
[133]. 
The effect of the oblique incidence can be expressed by the following equation: 
𝐷 (𝑓 + 𝑔, 𝑑) =  𝐷0(𝑓, 𝑔). (
𝑓 + 𝑑
𝑓 + 𝑔 + 𝑑
)
2
. 𝑂𝐹 (𝜃, 𝑑) 
where: g is the gap, f is the effective SSD (surface to virtual source distance) and OF 
is the obliquity factor. 
The results of this study showed that the surface dose ranged from 24 % - 60 % of 
the delivered dose in case of no brass bolus. The surface dose increased from 62 % - 
90 %, 64 % – 92 %, and 75 % – 94 % of prescription dose for the Face-up brass 
bolus, Face-down brass bolus and double brass bolus, respectively. The TE- bolus 
increased the surface dose more than the brass bolus. The surface dose increased to 





The increase in surface dose measured on the curved phantom was similar to the in 
vivo measurements on the IMRT thorax phantom of Manger et al. [135], who found 
that in the no-bolus case, the surface dose ranged from 40 % – 72% of the 
prescription dose, with the maximum value occurring at the point where the beam 
entry was most shallow. The brass bolus surface dose profile resembled the profile 
for the no-bolus case, except the surface dose increased from 75 % – 110 % of 
prescription dose. The surface dose under the tissue-equivalent bolus increased from 
85 %  – 109 % of prescription dose [137]. Healy et al. evaluated the increase in the 
surface dose for the patients and found that the brass bolus increased the surface dose  
from 81 % - 122 % of the prescribed dose [16]. Furthermore, it can be seen from 
Figure 6-6 that the dose at the phantom surface was clearly nonhomogeneous with 
brass mesh bolus, compared with using tissue- equivalent material, where this repeat 
mesh pattern of the brass bolus material was apparent on the film profiles.  
During measurements, the brass mesh bolus was very easy to place on a three-
dimensional convex surface of the breast phantom, as shown in Figure 6-2, while 
Superflab bolus cannot conform to the phantom’s surface. There were air gaps 
between the Superflab bolus material and phantom surface. This outcome was 
consistent with what other authors found [13, 16, 135].   
6.4 Conclusion 
This chapter aimed to study the feasibility of using the brass mesh bolus as an 
alternative to tissue equivalent bolus. From the data presented, it can be concluded 
that the brass bolus decreases the radiation build-up depth and thereby increases 
radiation dose delivered to the skin. The increases in surface dose for the brass bolus 




photon beam by only 0.6 % and 1.4 % for the one and two layers of brass bolus, 
respectively. It has been reported in the literature previously, that for 6 MV photon 
beam, three or four layers of the brass mesh would be required to produce the same 
surface dose as 0.5 cm of tissue-equivalent bolus material. In contrast, there is a 
considerable backscatter component of dose created by the high Z brass mesh as a 
megavoltage photon beam exits through the brass bolus. 
Due to the mesh brass construction, peak-to-trough dose variation beam profiles 
were measured at the surface under Face-up and Face-down brass bolus. This 
fluctuation decreased with depth, it reduced to 3.1 % and 2.3 % at 1 mm and 2 mm 
depth, respectively and it was almost uniform at 100 mm depth.  
The brass bolus has some interesting and desirable dosimetric properties over tissue-
equivalent bolus. The effect of the brass mesh bolus on percentage depth-dose curves 
beyond dmax is less than 0.4 %, which is compatible with the findings of other 
authors. Only one treatment plan is required when using the brass mesh throughout 
the course of treatment since brass mesh does not substantially change the number of 
monitor units (MUs) associated with the plan. Additionally, there is no need to model 
brass in the TPS. The greatest advantage of the brass bolus is its ability to conform to 
a curved patient surface with much fewer or no air gaps, which leads to producing 
more uniform dose distribution, compared with some standard commercially 
available tissue-equivalent materials. Some articles have concluded another 
advantage of brass over tissue-equivalent bolus is that the brass mesh achieved 
moderate erythema in the majority of patients (88 %) at the end of treatment at 
cumulative radiation doses of approximately 5 Gy. In vivo dose measurements 
showed that the  surface doses were found to be within 99 % ± 10 % of the 




Brass mesh has been successfully introduced into clinical practice in several 
institutions as an alternative to tissue-equivalent bolus, although usually for a 






















7 Chapter 7 Dosimetric Effect of Brass Mesh Bolus 
Construction on Skin Dose Measurements. 
7.1  Introduction 
Tissue-equivalent material bolus are commonly used during postmastectomy 
radiation therapy to provide an adequate dose build-up in the skin and superficial 
chest wall. The aim of this work was to investigate the dosimetric effects of the 
structure of the 2-mm fine brass mesh bolus on the skin dose by characterizing the 
skin dose spatial distribution with the Gafchromic EBT 3 film and the MOSkinTM 
dosimeter. 
7.2    Materials and Methods 
7.2.1 Beam profiles. 
Gafchromic EBT 3 film (Ashland ISP Advanced Materials, USA) from the same lot 
(batch no. 04071601) was used in all measurements in this research. 6 × 6 cm2 
Gafchromic EBT 3 film pieces were positioned at the centre of the 30 × 30 × 10 cm3 
solid water phantom at isocenter with 600 MU/min, 10 × 10 cm2 and 100 cm SSD. 
The beam profiles were measured at varying depths of 0, 1, 2, 3, 15 and 100 mm. 
These measurements were repeated for the case of one-layer Face-up brass bolus and 
double layer of brass bolus. The Gafchromic EBT 3 film was scanned pre-irradiation 
and post-irradiation using a 48-bit RGB (Red-Green-Blue) transmission film scanner, 
EPSON 10000XL Photo Flatbed Scanner (Epson America, Inc., Long Beach, CA), at 
a resolution of 72 dots per inch (DPI). To calibrate EBT 3 film under reference 




phantom at depth of 1.5 cm for 6 MV. To obtain the EBT 3 film calibrations, the 3 × 
3 cm2 EBT 3 film pieces were irradiated to a range of doses (20 cGy, 50 cGy, 1 Gy, 
2 Gy, 3 Gy, 5 Gy). 2-dimentional median filter was applied to reduce image noise 
[69]. For all dosimeter calibrations, the measurements were repeated three times and 
the average reading was used for analysis. The average uncertainty calculated across 
all the field size measurements was ± 2.3 % (1SD). 
7.2.2 Brass mesh spatial perturbation. 
The beam transmission through the brass mesh, both through the brass discs and 
spaces, as shown in Figure 6.1, for the case of Face-up and Face-down brass bolus 
were investigated with Gafchromic EBT 3 film. The EBT 3 film strips were placed 
on the surface of the solid water phantom. EBT 3 strip irradiated with 300 MU. The 
dose profiles through the centre of the strip were obtained. The measurements were 
performed for 6 MV, 100 cm SSD and 10 × 10 cm2 field size. The measurements 
were repeated for Face-up and Face-down brass bolus at surface and 10 cm depth. 
The beam profile was plotted as the dose as a percentage of dmax versus the distance 
(mm). 
7.2.3 Entrance dose measurements. 
The MOSkinTM dosimeter, with a faceup orientation, was placed at the central axis of 
the 6 MV photon beam on the surface of the solid water phantom. The brass discs of 
Face-up brass bolus were placed above the dosimeter. The measurements were 
performed under brass discs and then repeated under spaces in the brass mesh. The 
steps were repeated for the Face-down brass bolus. Finally, the gantry of the LINAC 
was rotated 1800 and the same procedures were repeated. The surface doses at the 




using the MOSkinTM dosimeter in Face-down orientation relative to the beam 
directional from 1800 in the slab solid water phantom for 10 × 10 cm2 at 100 cm 
SSD.  
7.3    Results and Discussions 
7.3.1 Beam profiles. 
Figure 7-1 displays the results of the EBT 3 Film showing the pattern for Face-up 
and Face-down mesh brass bolus at 0 mm depth and for the Face-up mesh brass 
bolus at 100 mm depth. 
 
Figure 7-1 EBT 3 Film showing the pattern for (a) Face-up mesh brass bolus at 0 mm 
depth, (b) Face-down mesh brass bolus at 0 mm depth, (c) Face-up mesh brass bolus 
at 100 mm depth. 
 
Figure 7-2.a and 7-2.b represent the dose profiles measured with 6 × 6 cm2 




phantom for the cases of no bolus, Face-up, Face-down brass bolus, double brass 
bolus, 0.5 cm and 1.0 cm TE- Superflab bolus. The oscillations seen in the profiles 
(peak-to-trough dose variation) measured under Face-up and Face-down brass bolus 
at surface were expected due to the mesh brass structure which resulted in 
inhomogeneous attenuation. The profile measured under the Face-down brass 
showed an inverted behaviour to the Face-up brass bolus. These fluctuations 
decreased with the double layer of the mesh brass. The PDD profiles measured under 
TE -Superflab bolus were uniform at surface and 100 mm. The 0.5 cm TE bolus has 
reduced the dose at depth by 5 - 10%. The effect of the mesh brass structure 
decreased with depth. Our results displayed that the peak-to-trough PDD variation 
reduced to 3.1 % and 2.3 % at 1 mm and 2 mm depth, respectively. At 100 mm 






Figure 7-2 Dose Beam Profiles measured under brass and TE-bolus at (a) surface and 
(b) 100 mm depth measured with the EBT 3 Film. 
7.3.2 Brass mesh spatial perturbation.  
The transmission of the dose through the brass discs and spaces in the mesh of the 
Face-up and Face-down brass bolus results are presented in Figure 7-3.a and Figure 
7-3.b and Table 7-1. The mesh bolus produced ripple dose profiles which resemble 
the mesh pattern. The percentage difference between the maximum and minimum 






Figure 7-3 Surface PDD (%) measured with the MOSkinTM, through the brass discs 
and spaces in the mesh for (a) Face-up and (b) Face-down brass bolus. (c) EBT 3 





Figure 7-4 Percentage difference between the maximum and minimum dose readings 
through brass discs and spaces in the mesh for Face-up and Face-down brass bolus. 
 
The peak-to-trough dose differences fluctuated from the average measurement 
through the brass spaces from -5 % to 5 % for Face-up mesh brass and from -6 % to 
9 % for Face-down mesh, whereas, the dose transmission difference fluctuated from 
the average measurement through the brass discs from -5 % to 6 % for Face-up mesh 
and from -7 % to 6 % for Face-down mesh brass bolus, as shown in Figure 7-3. 
Richmond et al. [157] found that the peak-to-trough dose differences is of the order 
of 12 % at its maximum. 
Table 7-1 The maximum and minimum surface PDD measured under the brass discs 
and spaces for Face-up and Face-down mesh brass bolus. 
 
spaces in mesh brass (%) discs in mesh brass (%) 
 
Face-up Face-down Face-up Face-down 
D (max) 58.8 56.3 61.6 59.3 
D (min) 48.8 41.5 50.3 43.3 
D (average) 54.1 ± 1.8 50.2 ± 3.6 56.2 ± 2.5 52.8 ± 3.6 
The Face-up mesh brass bolus increased the surface dose to approximately 4 % more 




transmission between brass spaces and discs were 2.15 % and 2.60 % for the Face-up 
and Face-down mesh bolus respectively. 
7.3.3 Entrance dose measurements. 
The compact size of the MOSkinTM dosimeter allowed accurate placement under the 
discs and spaces of the brass bolus.  
The Face-up brass bolus increased the surface dose from 19.2 % to 63.1 % and 51.2 
%, as measured under the brass discs and spaces, respectively. Whereas, the 
increments in the surface dose measurements when the brass bolus flipped out (Face-
down) on the surface of the phantom was slightly lower than Face-up brass 
measurements. For the case of Face-down brass bolus, the surface doses enhanced 
from 19.2 % to 61.5 % through brass discs and 41.3 % under brass spaces, Figure 7-5 
 
Figure 7-5 The measured surface doses with MOSkinTM dosimeter for the cases of 
Face-up and Face-down brass bolus. 
 
These results showed that the brass bolus increased the surface dose. The measured 
doses under the brass discs were more than the measured doses under brass spaces 
for both Face-up and Face-down brass cases. This is due to the fact that the enhanced 
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dose to the skin at the skin-mesh interface is due primarily to secondary charged 
particles produced in the mesh brass material. The percentage dose enhancement 
under brass discs were 43.9 % and 42.3 %, for Face-up and Face-down brass bolus, 
respectively, whereas under brass spaces, the % dose enhancement was 32.0 % and 
22.1 %, for Face-up and Face-down brass bolus, respectively. The percentage dose 
difference between Face-up versus Face-down brass measured were 1.6 % and 3.4 % 
under brass discs and spaces in mesh, respectively.  
Due to the backscatter of electrons, the exit dose was more than the entrance doses, 
as presented in Table 7-2. 
Table 7-2 The surface entrance and exit PDD measured with MOSkinTM under brass 
bolus. 
 








Entrance Dose (%) 19.2 ± 3.4 63.1 ± 2.1 51.2 ± 1.2 61.5 ±0.5 41.3 ±2.1 
Exit Dose (%) 47.9 ± 0.5 74.1 ± 0.4 72.1 ± 0.4 77.5 ±0.1 67.1 ±3.6 
 
It should be noted that there was a significant backscatter component of dose created 
by the high Z brass mesh as a megavoltage photon beam exits through the material, 
as is the case for tangential breast irradiation, when compared with the dose build-
down effect with no bolus being present.    
7.4   Discussion 
Face-up brass mesh has been successfully introduced into clinical practice in several 
institutions as an alternative to tissue-equivalent bolus, although usually applied for a 




superficial dose when used in conjunction with tangential irradiation geometries is 
complicated and requires careful consideration before clinical use.  
Based on the finding of this research, it is recommended to use the brass bolus on the 
Face-up orientation, reason being it produces less rippled dose profiles at the surface 



















8 Chapter 8 THE EFFECT OF SETUP ERRORS AND 
MOTION ON DOSE COVERAGE FOR BREAST 
RADIATION THERAPY 
8.1   Introduction 
Globally, breast cancer is the leading cancer site in females. It is estimated  that 1.4 
million new cases are diagnosed every year [164] and is ranked as the second most 
common cancer in the world [165]. In addition to this, breast cancer occurrences are 
increasing every year, particularly with younger patients [166]. The quality of 
surgery and the adequacy of the radiation treatment determine the outcome of breast 
conservation treatment, in terms of cosmetics, local control, and complication rate 
[167, 168]. The healthy tissues such as, skin is comparatively radiosensitive organ. It 
usually locates close to the target volume and logically receives a high radiation dose 
and may display different degrees of damage after certain doses of radiation therapy 
(RT). The most common expected RT Radiation dermatitis toxicities are skin 
erythema, breast edema, and breast fibrosis [169]. Furthermore, larger dose to skin 
may increase the risk of second malignancies, especially critical for breast cancer 
treatment [170]. Thus, physicians can use the skin dose sparing parameters to avoid 
radiation dermatitis damage and improve patient quality of life [169]. There are 
several factors that may influence the skin RT complications, one of these parameters 
is the treatment technique. 
Nowadays, more sophisticated and highly conformal radiation therapy techniques, 
such as intensity modulated radiation therapy (IMRT), have been used to treat breast 




improving the dose homogeneity and conformity over conventional techniques [17, 
18] and reducing doses to the organ at risks [171-173]. Volumetric modulated arc 
therapy (VMAT) is quickly being adapted as the best candidate radiation therapy 
(RT) technique to treat breast cancer in particular if nodal volumes are to be covered 
[174-178].  
Quality assurance programs have become fundamental in radiation therapy to gain 
the best possible therapeutic results [179, 180]. For complex treatment techniques 
such as IMRT and VMAT, the most common approach to QA is based on pre-
treatment patient-specific quality assurance (QA) by using specialised 2D detectors 
arrays or film measurements in phantoms. However, some previous studies have 
shown that there are still some errors in treatment delivery due to the lack of 
detection of clinically significant differences when pre-treatment verification is used 
[181, 182].  
Real-time in vivo dosimetry is the most appropriate method, which could be used to 
check simultaneously both the treatment technique during delivery and the actual 
accumulated dose delivery. Using real-time in vivo dosimetry can detect errors 
between the planned and the delivered doses during the treatment and avoid potential 
consequences [22, 23]. 
Currently, many detectors have been used routinely as in vivo dosimeters. However, 
most of the available real-time dosimeters are not able to measure the skin dose at a 
depth of 0.07 mm as recommended by ICRP.  
Recently, most of radiation treatment centres tend to use image guided radiation 
therapy (IGRT) to setup the patients accurately. Several works on the dosimetric 
impact of respiratory motion and patient setup error have been performed in several 




image sets [183, 184]. They concluded that the dosimetric impact of respiratory 
motion was clinically insignificant for the conventional wedged tangential technique 
and segmental IMRT. Richter et al. [185] evaluated the influence of breathing 
motion in postoperative whole-breast radiation therapy with four-dimensional (4D) 
dose calculation based on respiration-correlated CTs and with electronic portal 
images (EPID), which was acquired in cine mode during treatment. It was concluded 
that the maximum breathing-induced motion amplitude was smaller than 4 mm in all 
patients which agrees with previous literature data. T. Furuya et al. [186] 
investigated the dosimetric impact of respiratory breast motion and daily setup error 
on whole breast tangential irradiation using three irradiation techniques; conventional 
wedge (CW), field-in-field (FIF) and irregular surface compensator (ISC). It was 
reported that for the anterior-posterior (AP) respiratory motion and setup error of a 
single fraction, the D95, V95 and dose homogeneity index did not significantly differ 
from the original plans for FIF and CW techniques, but it differed significantly for 
ISC technique. 
The dosimetric impact of respiratory motion was clinically insignificant for the CW 
technique and segmental IMRT [186]. Additionally, all the available data does not 
give an accurate measured skin dose since all these data are based on conventional 
3D treatment planning and do not consider breathing motion during delivery of 
irradiation [185]. 
Considering the importance of these issues, the current study aims to measure the 
effects of setup errors and changes in patient geometry on the epidermal skin dose 
using the MOSkin dosimeter for a range of techniques, including 3D-CRT, IMRT 
and VMAT. Thus, allowing the stability of epidermal skin dose to be compared 




8.2    Materials and Methods 
8.2.1 MOSkinTM dosimeter 
In this research, two sets of MOSkinTM probes were utilised. The set number 1 
consists of two MOSkinTM probes, which were connected by a 5-meter cable to the 
MOSkinTM conventional wired data acquisition system that connected to the laptop. 
All measurements with set 1 were carried out under a Varian Clinac iX linear 
accelerator (Varian Medical System, Palo Alto, USA). The set number 2, consists of 
four MOSkinTM probes, that were connected wirelessly to MOSkinTM DAQ system. 
The newly developed wireless MOSkinTM dosimetry system, is making MOSkinTM 
response independent on the temperature, small in size, battery operated and does not 
require cabling. The measured dose uncertainty is lower than 0.5 cGy [187]. They 
were calibrated at the reference condition using a Varian TrueBeam (Varian Medical 
System, Palo Alto, CA, USA) linear accelerator.   
8.2.2 Comparison of different techniques for Real-time in vivo Skin Dose 
Measurements.  
8.2.2.1 Treatment Planning for in vivo Skin Dose in CIRS IMRT Phantom. 
A CIRS Breast IMRT phantom (Model 002LFC) with left side breast attachment was 
used in this study. The phantom is manufactured from unique proprietary materials 
that approximate water, bone and lung within 1 % from 50 keV to 25 MeV. Inserts 
with densities of 0.21 g/cm3, 1.60 g/cm3, 1.06 g/cm3, and 0.96 g/cm3 are used to 
represent lung, bone, muscle and adipose, respectively.  
Computed Tomography (CT) images of the CIRS Breast IMRT phantom were 
acquired in the supine position with 2 mm slice thickness for radiation therapy 




TPS. The clinical target volume (CTV) was contoured as the whole breast insert with 
5 mm skin retraction and then the planning target volume (PTV) was contoured as 
the CTV with superior/inferior and posterior extension. The ipsilateral lung was 
contoured as organs at risk (OAR) in each slice. Finally, the skin was contoured as a 
5-mm strip extending from phantom outline to the anterior surface of PTV. The 5-
mm thickness of skin was chosen to include the three layers of skin (epidermis, 
dermis, and hypodermis), and this thickness was adopted by some authors in head 
and the neck IMRT to achieve skin dose reduction [188]. 
Three treatment plans with various techniques were created. 50 Gy in 25 fractions 
was delivered for 6 MV photon beam. The three treatment plans were generated for 
the phantom measurements: 3-Dimensional Conformal Radiation Therapy (3D-CRT) 
with two tangential fields, Intensity Modulated radiation therapy (IMRT) with two 
tangential fields and Volumetric Modulated Arc Therapy (VMAT) with four partial 
arcs. The dose constrains used for optimisation were V20Gy ≤ 45.0 % and V30Gy ≤ 
35.0 % for Ipsilateral Lung, V20Gy ≤ 25.0 % and V30Gy ≤ 20.0 % for whole Lung, 
V5Gy ≤ 15.0% for Contralateral Breast.  
All plans were created using RayStation treatment planning system with Collapsed 
Cone Convolution (CCC) dose calculation algorithm, inhomogeneity correction and 
calculation grid size of 3 × 3 mm2 was used for optimization and 1 × 1 mm2 for final 
dose calculation. 
8.2.2.2 Delivery of different techniques in CIRS IMRT phantom 
The CIRS Breast phantom was irradiated using a Varian Clinac iX (Varian Medical 
System, Palo Alto, CA, USA). For accurate positioning, the phantom was aligned on 
the couch by the aid of room lasers and Cone Beam Computed Tomography 




different positions. The first position was near the nipple of the breast and the second 
position was near the entry side exit. The purpose of adding them is to denote the 
position of the MOSkinTM dosimeter on the image to assist the planner in finding the 
correct measurement location in the treatment planning system. These fiducial 
markers were then removed carefully after the alignment of the phantom in the couch 
and replaced with the two calibrated MOSkinTM dosimeters, the set number 1 
MOSkinTM probes, as shown in Figure 8-1. The face-up MOSkinTM probes were 
taped onto the phantom and care was taken to have assured that the tape was not 
covering the sensitive volume of the MOSkinTM and also to have no air gaps behind 
the dosimeters and the surface of the phantom. The MOSkinTM dosimeters were then 
connected via cable to the MOSkinTM readout system, as shown in Figure 8-2.  
The three original breast plans: 3D-CRT (two tangential fields), IMRT plan (two 
IMRT tangential fields) and VMAT plan (four partial Arcs) were delivered 
individually. The measurements were repeated for three times. For each delivery, the 
individual MOSkinTM probe recorded the reading of accumulated dose at 30 seconds 
after beam off. To simulate the effects of setup errors, respiratory motion and breast 
deformation, amongst other positional uncertainties, measurements were performed 
with the phantom in two different offsets. The offsets focused on a surface motion 
perpendicular to the tangential beam direction and were applied by shifting the 
isocenter laterally and anteriorly. The first offset was a surface expansion of 14 mm 
(isocenter shift 10 mm posterior and 10 mm lateral), it is called Offset (1) delivery, 
and the second a surface contraction of 14 mm (isocenter shift 10 mm anterior and 10 
mm lateral), it is called Offset (2) delivery. The same MU number as the original 








Figure 8-1 Positions of the MOSkinTM dosimeters on the CIRS IMRT Phantom. 
 




8.2.3 Effect of patient setup on skin dosimetry for different VMAT plans. 
8.2.3.1 Treatment Planning for On-line measurements in CIRS IMRT Phantom. 
The CT images were transferred to the Eclipse treatment planning system (Varian 
Oncology Systems, Palo Alto, CA) and then the target and the organs at risk (OARs) 
were delineated, same as mentioned in section 8.2.2.  
A Volumetric Modulated Arc Therapy (VMAT) plan was created using Acuros XB 
version 13.6 algorithm with inhomogeneity correction and calculation grid size of 2.5 
× 2.5 mm2 was selected for dose calculation. 50 Gy in 25 fractions was delivered for 
6 FFF MV photon beam. The plan consists of 4 partial arcs: 1st Arc: 285° - 315°, 2nd 
Arc: 315° - 285°, 3rd Arc: 105° - 135°, 4th Arc: 135° - 105°. The VMAT optimisation 
aimed to achieve high homogeneity of the dose distribution within the treated breast 
volume and to minimise hot dose spots throughout the treated breast volume as per 
International Commission on Radiation Units and Measurements 50 (ICRU50) 
guideline. The dose distribution in the transverse slice is shown in Figure 8-3. A 
Three different treatment plans were generated to highlight the various planning 
issues encountered in this scenario. One plan was performed with adding virtual 
bolus of 0.5 cm thickness, which was added for optimisation, and removed before 
final dose calculation and not used for the treatment. The purpose of adding the 
virtual bolus is to help the optimiser to compensate dose at the skin based on 
suboptimal calculated dose values. Other authors specified another advantage of 
adding virtual bolus, which is to compensate for any variations in setup position such 
as patient motion and setup errors [189-192]. The optimisation aims to cover the 
target extending into the bolus and this simulate patient motion or setup error. This 
plan is called PTV_Bolus_Plan. The other two plans were created without bolus, to 




PTV_Plan, the PTV volume was used as target in the optimization. This means the 
optimiser is trying to pump dose right up to the skin surface in the dose build-up 
region. Finally, the breast phantom was shifted to 3.5 mm to the right side and to 3.5 
mm to up, and the three plans were recalculated.  
 
 
Figure 8-3 VMAT Field arrangements and the axial dose distribution (a) CTV plan, 
(b) PTV plan, (c) PTV-Bolus plan. 
8.2.3.2 Delivery of VMAT plans in CIRS IMRT Phantom  
For the absolute dose distributions measurement, the CIRS phantom images and 
organ contours were transferred to a Varian TrueBeam (Varian Medical System, Palo 
Alto, CA, USA) linear accelerator for treatment delivery. The phantom was aligned 
on the couch using the room laser alignment and Cone Beam Computed Tomography 
(CBCT) scan. Four fiducial markers were placed on the surface of the phantom in 
four different positions. These fiducial markers were then removed carefully after the 




MOSkinTM dosimeters, as shown in Figure 8-4. The probes were taped onto the 
phantom and care was taken to assure that the tape was not covering the sensitive 
volume of the MOSkinTM and also to have no air gaps behind the dosimeters and the 
surface of the phantom. The MOSkinTM dosimeters were then connected to the 
wireless readout system, which transferred data wirelessly to a laptop provided with 
the software, as shown in Figure 8-5. This software visualised a graphical display of 
the contribution from each field to the overall surface dose during the treatment 
delivery.   
For each treatment plan, the MOSkinTM probes recorded the total doses delivered for 
each of the VMAT arc. Then the phantom was shifted to 3.5 mm laterally and 3.5 
mm vertically, and the measurements were taken for the three original plans 
(CTV_Plan, PTV_Plan and PTV_Bolus_Plan). The process was repeated twice for 
each plan. Finally, the MOSkinTM measured doses were plotted as a function of time 
over the whole course of each treatment fraction. 
 






Figure 8-5 On-line CIRS Breast IMRT Phantom setup. 
8.3 Results 
8.3.1 MOSkinTM dosimeter 
The average Calibration Factor (CF) for the MOSkinTM probes used in this study 
were 2.55 ± 0.01 mV / cGy and 2.28 ± 0.01 mV / cGy for the set number 1 
(conventional wired MOSkinTM probes, calibrated using Varian Clinac iX) and the 
set number 2 (temperature independent wireless MOSkinTM probes, calibrated using 
TrueBeam), respectively.  
8.3.2 Comparison of different techniques for Real-time in vivo Skin Dose 
Measurements.  
Table 8-1 presents the skin dose measured on CIRS IMRT Breast Phantom with the 
set number 1 MOSkinTM probes in position 1 and position 2 for the deliveries of the 
original plans, and with the 1 cm phantom offset to the right and up side and 1 cm 






Table 8-1 Summary of the predicted skin doses and measured skin doses for each 












3D-CRT Tang. Field 1  58.8 ± 0.4 59.9 ± 0.4 58.4 ± 0.4 
Tang. Field 2  49.0 ± 0.3 50.2 ± 0.4 48.7 ± 0.3 
Total 156 107.8 ± 0.7 110.2 ± 0.8 107.1 ± 0.7 
IMRT Field 2  45.0 ± 0.3 28.3 ± 0.3 46.0 ± 0.3 
Field 1  53.8 ± 0.4 35.0 ± 0.3 55.6 ± 0.4 
Total 146 98.8 ± 0.7 63.3 ± 0.6 101.5 ± 0.7 
VMAT Arc 1  24.1 ± 0.3 8.3 ± 0.4 25.8 ± 0.3 
Arc 2  23.4 ± 0.3 17.7 ± 0.3 22.7 ± 0.3 
Arc 3  24.4 ± 0.3 21.7 ± 0.3 23.1 ± 0.3 
Arc 4  12.4 ± 0.3 7.5 ± 0.4 15.9 ± 0.3 
Total 153 84.2 ± 1.2 55.2 ± 1.4 87.5 ± 1.2 
Position 
2 






3D-CRT Tang. Field 1  26.8 ± 0.3 28.8 ± 0.3 23.6 ± 0.3 
Tang. Field 2  49.7 ± 0.4 51.1 ± 0.3 47.6 ± 0.3 
Total 106 76.5 ± 0.7 80.0 ± 0.6 71.1 ± 0.6 
IMRT Field 2  52.5 ± 0.4 52.0 ± 0.3 51.7 ± 0.3 
Field 1  25.6 ± 0.3 26.0 ± 0.3 24.8 ± 0.3 
Total 107 78.1 ± 0.7 78.0 ± 0.6 76.6 ± 0.6 
VMAT Arc 1  13.5 ± 0.3 12.8 ± 0.3 11.6 ± 0.3 
Arc 2  10.1 ± 0.3 11.2 ± 0.3 9.9 ± 0.3 
Arc 3  25.3 ± 0.3 26.0 ± 0.3 24.0 ± 0.3 
Arc 4  25.3 ± 0.3 24.8 ± 0.3 25.7 ± 0.3 
Total 118 74.3 ± 1.2 74.8 ± 1.2 71.3 ± 1.2 
 
Figure 8-6 displays the percentage skin dose discrepancies between the original plans 
and the phantom deliveries with 1 cm offset (1) shown in Figure 8-6.a and 1 cm 






Figure 8-6 Percentage dose difference between the measured dose for the original 
plan and the measured dose for: a- phantom offset (1) delivery and b- phantom offset 
(2) delivery. 
8.3.3 Effect of patient setup on skin dosimetry for different VMAT plans. 
By the aid of CBCT, the positions of the set number 2 MOSkinTM detectors were 
placed accurately (within +/-1mm) in their pre-determined positions. The results of 





































(a) Original plan dose vs offset (1) delivery.

































(b): Original plan dose vs offset (2) delivery.




Table 8-2 Total skin dose comparison between the calculated dose with TPS and the 
dose measured with four MOSkinTM dosimeters for three different treatment plans: 












CTV_Plan measured Dose (cGy) 104 ± 0.4 41 ± 0.3 33 ± 1.3 75 ± 0.2 
calculated Dose (cGy) 92 80 91 64 
% Difference 12 -95 -176 15 
CTV_offset_Plan measured Dose (cGy) 102 ± 0.4 14 ± 0.1 11 ± 0.5 73 ± 0.2 
calculated Dose (cGy) 124 35 86 30 
% Difference -22 -150 -682 59 
PTV_Plan measured Dose (cGy) 106 ± 0.4 48 ± 0.3 40 ± 0.3 89 ± 0.4 
calculated Dose (cGy) 90 85 99 76 
% Difference 15 -77 -148 15 
PTV_offset_Plan measured Dose (cGy) 107 ± 0.4 20 ± 0.3 15 ± 0.3 85 ± 0.5 
calculated Dose (cGy) 125 46 93 41 
% Difference -17 -130 -520 52 
PTV_Bolus_Plan measured Dose (cGy) 104 ± 0.2 84 ± 0.3 86 ± 0.8 78 ± 1.7 
calculated Dose (cGy) 94 92 92 94 
% Difference 10 -10 -7 -21 
PTV__Bolus_offset_Plan measured Dose (cGy) 112 ± 0.6 43 ± 0.3 46 ± 0.6 79 ± 1.2 
calculated Dose (cGy) 128 70 88 88 
% Difference -14 -63 -91 -91 
 
Figure 8-7 The skin dose measured in real-time during the delivery of VMAT plans 
with MOSkinTM probes in the CIRS IMRT Breast phantom for the three original 








Figure 8-7 The skin dose measured in real-time during a single-treatment arc VMAT 
delivery for CRT_Plan, PTV_Plan, PTV_Bolus_Plan and the plans with 3.5 mm 
offset. (Presented graphs automatically provided by MOSkinTM reader). 
 
Figure 8-8 shows the percentage differences of the measured skin dose between the 





Figure 8-8 Percentage dose difference between the original measured plans and their 
3.5 mm Offset measured plans for the four positions of the MOSkinTM. 
 
The measured integral dose for the original measured plans deviated from the 
calculated plans by approximately less than 8 % and 5 % for detector 1 and detector 
4, respectively, whereas, this difference increased to above 48 % and 46% with the 
detector 2 and 3, respectively.  
The percentage deviations between the integral measured skin dose and the 
calculated dose is shown in Figure 8-9. 
 
Figure 8-9 Percentage of the skin dose deviations between the measured and 




















































This research demonstrated that an offset in the position of the original plan led to a 
significant discrepancy between the calculated and the measured doses due to 
inherent fluence variations in IMRT and VMAT deliveries. This discrepancy varied 
between techniques and positions on the surface of the phantom. The advanced 
techniques such as IMRT and VMAT exhibited significant offset influence compared 
to the 3D-CRT. For 1cm right and up phantom shift, the measured doses decreased 
by more than 37 % for IMRT (F2) and 65 % for VMAT (Arc 1), whereas only 7.8 % 
for 3D-CRT (F1) as shown in Figure 8-6. 1cm left and down phantom showed less 
offset effect than the right and up shift. The maximum percentage dose difference 
was recorded for VMAT-Arc 4 was less than 30 %, 3.3 % for IMRT (F1), and 11.4 
% for 3D-CRT. 
As shown in Table 8-1, the skin dose was with 3D-CRT technique compared to the 
IMRT and VMAT techniques. The dose increased from the medial to the lateral 
direction with highest dose being around the nipple. It was approximately 108 % for 
3D-CRT, 99 % for IMRT and 84 % for VMAT of the prescribed dose near the 
nipple, and it was 106 %, 107 % and 118 %, for 3D-CRT, IMRT and VMAT, 
respectively. Almberg et al. [193] concluded that 7-field IMRT showed 4 - 5 % 
reduction of surface dose compared to tangential wedged fields.  
Dogan and Glasgow [131] reported that IMRT itself does not contribute to greater 
skin doses. They concluded that the increase in surface dose due to the oblique IMRT 
beams was similar to the increase in the dose with the use of open beams.  
The position of the MOSkinTM detector on the surface of the phantom was in a high 
dose gradient region, so the uncertainty in the detector position and verification point 




seen in Figure 8-6, the detector in position 1, which was near the breast nipple, 
expressed higher percentage dose contradiction than the position 2 detector, which 
was in medial side for IMRT and VMAT techniques. This result matched with the 
results in Figure 8-8, where, detector 2 and 3 expressed higher percentage dose 
differences than the other detector positions for all plans. It reached above 46 % and 
48 % for position 3 and position 2, respectively.  
Several studies investigated the accuracy of the TPS algorithms in calculating the 
superficial dose in breast treatment [53, 59, 131, 194]. Although advanced TPS 
algorithm was used in this study, the accuracy of Acuros and RayStation were not 
suitable for calculating superficial dose in breast treatment. This is not surprising as 
the advanced calculation pertains to secondary charged particle transport and not 
electron contamination. Standard TPSs don’t really have any useful information 
about surface dose at 0.07 mm depth, the minimum grid size they have is 1 mm. At 
this point the reported TPS dose is just interpolated between closest two voxels, 
usually one in air and one at a depth of 1-2 mm in the breast. Chow et al. [195] 
compared the Monte Carlo calculation with the calculation accuracy of a 
superposition/convolution algorithm for oblique beams and reported that both the 
AAA and collapsed cone convolution (CCC) algorithms cannot accurately calculate 
dose distribution at depths less than 2 mm. Our results in Table 8-1 and Table 8-2 
presented the differences between the calculated and the measured doses and confirm 
this.  
It can be noted in Figure 8-9 that the PTV_Bolus_Plan exhibited less dose difference 
between the original measured plan and calculated plan, as well as between the offset 
measured deliveries and the calculated plans. That is because the target surface was 




to reduce the impact of setup error. The measurements confirmed the effectiveness of 
the virtual bolus technique.  Previous studies concluded that the accuracy of the TPS 
increased with depth. Mutic et al. [194] observed that the IMRT doses calculated by 
the planning software were overestimated by 25 % at the surface and 5 % at 1 mm 
below the surface as compared to the doses measured by the parallel-plate chamber.  
The standard regimen of the total dose delivers to treat the breast cancer cases is at 
least 15 fractions [196]. Thus, the probability for the uncertainty in the positioning is 
high. One of the objectives of the current work was to study the feasibility of using 
MOSkinTM dosimeters as a part of the in vivo dosimetry to detect the dose differences 
between the original and the daily plan deliveries in real-time during the treatment 
for each Arc or field. To use this approach, the position of the MOSkinTM probes 
would need to be consistent for each treatment fraction, and this can be performed 
within +/- 1 mm by the aid of the CBCT. Then the MOSkinTM readout software 
import the measured plan, delivered during the 1st fraction, before the treatment with 
a second fraction started. The delivered dose could then be monitored in real-time 
and treatment can be stopped if the dose discrepancy exceeds the tolerance level or 
modification in dose delivery during the next fraction can be made.  
Without mentioned precautions, any small shift in the MOSkinTM positioning on the 
breast corresponding to original plan could lead to a large difference in the dose 
exported from the planning treatment system, as shown in the results of this study. In 
this work, the original measured plan compared with the phantom offset delivery. 
The MOSkinTM readout software allowed to display the accumulated dose from each 
detector during the treatment deliveries, as shown in Figure 8-7. It can be seen from 
this Figure, that the dose differences in the profile plots can be monitored in real-time 




the percentage differences of the accumulated measured skin dose between the 
original plans and the deliveries with the 3.5 mm phantom shifts. For detector 2, the 
percentage dose discrepancy was 66 % between CTV and CTV_Offset plan, 58 % 
between PTV and PTV_Offset plan and 48 % between PTV _Bolus and 
PTV_Bolus_Offset plan. This percentage increased with detector 3, where it reached 
to 68 % between CTV and CTV_Offset plan, 64 % between PTV and PTV_Offset 
plan and 46 % between PTV _Bolus and PTV_Bolus_Offset plan. The drop between 
clinical and offset plans are larger. This may be due to set up error, a 3.5 mm shift 
will move the measurement point right to the field edge so any slight set-up error will 
have a significant impact on dose measurement. 
Monitoring the skin dose delivery during the treatment, will be the useful way to 
understand that treatment delivery is correct in terms of correct patient positioning 
and/or plan execution. MOSkinTM is the only currently available real-time dosimeter, 
which can be used to read the skin dose in real-time during the treatment providing 
an effective tool for in vivo skin dosimetry QA. 
On-line skin dose measurements could be used to monitor and detect the skin dose 
during the breast treatment as currently do not exist TPS accurately predicting the 
surface dose and as demonstrated disagreement can be large for all mentioned 
techniques of treatment delivery. Accurate knowledge of the skin dose is important 
to avoid skin damage and bad cosmetic outcome of the treatment. Comparison of 
real-time in vivo skin dosimetry with MOSkinTM with TPS-calculated surface dose at 
depth 0.07 mm is not a plausible option for patient specific QA. However, 
MOSkinTM real-time skin dosimetry, due to its sensitivity to detect wrong patient 
positioning or wrong treatment delivery or both, is suitable for avoiding such errors 




9 Chapter 9 Conclusions  
This thesis started by providing a background about the skin dosimetry, the breast 
cancer and breast radiation therapy techniques. Moreover, it gave some details about 
the current in vivo dosimeters.  
Then it provided   description of the instruments used in this project. It provided 
description of the newly developed Skin diode dosimeter, and then a brief 
information about its electronic readout system (TERA) and data acquisition system. 
It also covered some details about the other dosimeters used in this thesis such as the 
MOSkinTM, and its readout system, film dosimetry, advanced Markus chamber and 
Attix ionization chamber. Finally, it outlined in details the used brass mesh bolus. 
This thesis had a three major goals. The first aim was to investigate the feasibility of 
using the newly developed n- type Skin dosimeter with 7 µm thick epitaxial layer for 
in vivo dosimetry. This dosimeter was successfully characterised on the surface of a 
water-equivalent RW3 slab phantom simulating the condition for in vivo skin 
dosimetry for external megavoltage photon beam breast treatments.  The Skin diode 
expressed a linear dose response over a dynamic range from 50 to 500 cGy for both 6 
and 18 MV. Comparing to Attix chamber, the Skin diode showed the ability to 
measure PDD within 2.3 % beyond the build-up region and it measured a percentage 
surface dose of 25.3 ± 2.0 % and 19.2 ± 2.3 % for 6 MV and 18 MV photon beams, 
respectively. The Skin diode showed an adequate response to radiation of different 
field sizes in measuring of output factor (OF). There was an agreement between the 
Skin diode and MOSkinTM dosimeter for all field sizes larger than 2.5 × 2.5 cm2, 




observed for the Skin diode for 6 and 18 MV photon fields (within an experimental 
error). The agreement in the exit dose measurements between the Skin diode and 
Attix chamber was within ± 2.4 %. The Skin diode shows promise as a tool for in 
vivo skin dosimetry. Future work is required for robust design of the Skin diode and 
light protection while keep WED 0.07 mm. 
This thesis accomplished the second aim by investigating the feasibility of using the 
2 mm brass mesh bolus as an alternative to tissue- equivalent (TE) bolus for post 
mastectomy chest wall cancer.  The effect of brass bolus on dose build-up at the 
entrance surface, the beam exit, skin dose profiles, percentage depth doses and the 
effect of the brass mesh mechanical structure on the skin dose for curved phantom 
using MOSkinTM, Gafchromic EBT 3 film and an Advanced Markus ionization 
chamber have been investigated. Data were acquired for the case of: no bolus, Face-
up bass bolus, Face-down brass bolus, double brass bolus, 0.5 cm and 1.0 cm of 
Superflab TE bolus. From the data presented in chapters of this thesis, it can be 
concluded that the brass bolus decreases the dose build-up depth and thereby 
increases radiation dose delivered to the skin. The increase in surface dose for the 
brass bolus are less than tissue-equivalent bolus used in this study. The brass mesh 
bolus attenuated the 6 MV photon beam by only 0.6 % and 1.4 % for the one and two 
layers of brass bolus, respectively while dose measured at depth 10cm in a phantom. 
The surface dose measured with MOSkinTM dosimeter increased from 19.2 ± 1.0 % 
to 63.1± 2.1 % under Face-up brass discs, 51.2 ± 1.2 % under Face-up brass spaces, 
61.5 ± 0.5 % under Face-down brass discs, and 41.3 ± 2.1 % under Face-down brass 
spaces. The percentage difference in the dose measured under brass discs between 
Face-up versus Face-down was less than 2 % for entrance dose and 10 % for exit 




for entrance dose and about 5 % for the exit dose. Gafchromic EBT 3 film 
measurements show that the mesh bolus produced ripple beam profiles due to the 
mesh brass mechanical structure. It has been reported in the previous literature, that 
for 6 MV photon beam, three or four layers of the brass mesh would be required to 
produce the same surface dose as 0.5 cm of tissue-equivalent bolus material. In 
contrast, there is a considerable backscatter component of dose created by the high Z 
brass mesh as a megavoltage photon beam exits through the brass bolus. Due to the 
mesh brass mechanical structure, a peak-to-trough dose variation profiles were 
measured at the surface under Face-up and Face-down brass bolus. This fluctuation 
decreases with the depths, it reduced to 3.1 % and 2.3 % at 1mm and 2mm depth, 
respectively and it was almost uniform at 100 mm depth. The brass bolus has some 
interesting and desirable dosimetric properties over tissue-equivalent bolus. The 
effect of the brass mesh bolus on percentage depth-dose curves beyond dmax is less 
than 0.4 %, which is compatible with the findings of other authors. It has been 
demonstrated, that only one treatment plan is required when using the brass mesh 
throughout the course of treatment since brass mesh does not substantially change 
the number of monitor units (MUs) associated with the plan. Additionally, there is no 
need to model brass in the TPS. The greatest advantage of the brass bolus is its 
ability to conform to a curved patient surface with much fewer or no air gaps, which 
leads to a more uniform dose distribution, compared with some standard 
commercially available tissue-equivalent materials. Some articles have concluded 
another advantage of brass over tissue-equivalent bolus is that the brass mesh 
achieved moderate erythema in the majority of patients (88 %) at the end of 
treatment at cumulative radiation doses of approximately 5 Gy. In vivo dosimetry 




the prescribed dose on average using brass mesh as TEB [16]. Face-up brass mesh 
has been successfully introduced into clinical practice in several institutions as an 
alternative to tissue-equivalent bolus, although usually for a percentage of treatment 
fractions. However, the effect of the mesh on surface and superficial dose when used 
in conjunction with tangential irradiation geometries is complicated and requires 
careful consideration before clinical use that is clear from this study.   
The utilisation of sophisticated treatment techniques such as IMRT and VMAT in 
breast radiation therapy due to their dosimetric advantages has increased. 
Consequently, the delivery of doses has become more complicated and skin dose 
prediction is poor by all TPS. On-line in vivo skin dosimetry has been demonstrated 
to have a significant advantage and can be suggested for verification of correctness 
of treatment delivery in real time by comparison skin doses during delivery of 
consecutive fractions. Additionally, to check the actual skin dose delivered to the 
patient the skin in vivo real time dosimetry can be used to pick up possible errors in a 
patient setup and / or dose delivery consistency from one fraction to another at any 
stage of delivery. It was demonstrated that on-line skin dose measurements could be 
used to monitor and detect the dose differences between the original plan and the 
offset plans mimicking wrong patient set up, and thus reduce the uncertainty in dose 
delivered to the patients and improve the quality of the treatment. The real-time 
MOSkinTM dosimeter has ability to display the measured dose in real time during the 
VMAT deliveries for each individual as well as the total dose at the point of 
MOSkinTM dosimeter placement and compared between the original plan and the 
offset plan deliveries. The third achieved goal in this thesis was to measure the 




possibility to detect inconsistencies at any stage of the IMRT and VMAT delivery 
during the breast treatment with a real- time MOSkinTM dosimeter.  
In the 1st part, it was found that the phantom offset significantly changed the skin 
doses relative to measured originally at the same points on the breast for 37 % for 
IMRT and 65 % for VMAT, while not essentially for 3D-CRT, 7.8 %.  In the 2nd 
part, the percentage differences of the accumulated measured skin dose between the 
original plans and 3.5 mm phantom offset deliveries were 66 % between CTV and 
CTV_Offset plan, 58 % between PTV and PTV_Offset plan and 48 % between PTV 
_Bolus and PTV_Bolus_Offset plan for detector 2 (centre point). This percentage 
increased for detector 3 (entry point), where it reached 68 % between CTV and 
CTV_Offset plan, 64 % between PTV and PTV_Offset plan and 46 % between PTV 
_Bolus and PTV_Bolus_Offset plan. Additionally, the predicted and measured skin 
dose during the breast treatment can differ for all considered TPS and delivery 
techniques as much as 176 %. From the presented data, it can be concluded that any 
small shift in the treatment setup can lead to high skin dose variation, especially for 
the sophisticated dose delivery techniques. However, accurate placement of the 
MOSkinTM on a patient body is a challenge and can be verified by on board cone 
beam CT. On-line skin dose measurements could be used to monitor the skin dose 
during the breast treatments as current TPS algorithm do not accurately predict it.  
It can be concluded that the MOSkinTM is a suitable real-time candidate dosimeter to 
be used for the on-line in vivo skin dosimetry to avoid certain set-up errors in breast 
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